Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

 

 

Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September  3 0 , 2014

 

or

 

 

 

Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from                    to                  

 

Commission File Number: 000-20086

 

UNIVERSAL HOSPITAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

Delaware

 

41-0760940

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)

 

6625 West 78th Street, Suite   300

Minneapolis, Minnesota 55439-2604

(Address of principal executive offices, including zip code)

 

(952) 893-3200

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant: (1)   has filed all reports required to be filed by Section   13 or 15(d)   of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)   has been subject to such filing requirements for the past 90 days.     Yes    No  

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule   405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes    No  

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule   12b-2 of the Exchange Act (Check one):

 

 

 

 

 

 

 

 

Large accelerated filer

 

 

Accelerated filer

 

Non-accelerated filer

 

 

Smaller reporting company

 

(Do not check if a smaller reporting company)

 

 

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule   12b-2 of the Exchange Act).   Yes    No  

 

Number of shares of co mmon stock outstanding as of November   6 , 2014:  1,000

 

 

 


 

Table of Contents

Universal Hospital Services, Inc.

Table of Contents

 

 

 

 

 

 

 

 

 

 

Page

PART I -  FINANCIAL INFORMATION  

 

 

 

 

 

 

 

ITEM 1.  

 

Consolidated Financial Statements (unaudited)

 

 

 

 

 

 

 

 

 

Consolidated Balance Sheets — September  30, 2014 and December 31, 2013

 

 

 

 

 

 

 

 

Consolidated Statements of Operations—Three and nine months ended September  30, 2014 and 2013

 

 

 

 

 

 

 

 

Consolidated Statements of Comprehensive Loss —Three and nine months ended September  30, 2014 and 2013

 

 

 

 

 

 

 

 

Consolidated Statements of Cash Flows — Three and nine months ended September  30, 2014 and 2013

 

 

 

 

 

 

 

 

Notes to Consolidated Financial Statements

 

 

 

 

 

 

ITEM 2.  

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

27 

 

 

 

 

 

ITEM 3.  

 

Quantitative and Qualitative Disclosures About Market Risk

 

40 

 

 

 

 

 

ITEM 4.  

 

Controls and Procedures

 

40 

 

 

 

 

 

PART II - OTHER INFORMATION  

 

 

 

 

 

 

 

ITEM 1.  

 

Legal Proceedings

 

41 

 

 

 

 

 

ITEM 1A.  

 

Risk Factors

 

41 

 

 

 

 

 

ITEM 2.  

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

41 

 

 

 

 

 

ITEM 3.  

 

Defaults Upon Senior Securities

 

41 

 

 

 

 

 

ITEM 4.  

 

Mine Safety Disclosures

 

41 

 

 

 

 

 

ITEM 5.  

 

Other Information

 

41 

 

 

 

 

 

ITEM 6.  

 

Exhibits

 

42 

 

 

 

 

 

Signatures  

 

 

 

43 

 

1


 

Table of Contents

PART   I - FINANCIAL INFORMATION

 

Item 1. Consolidated Financial Statements — Unaudited

Universal Hospital Services,   Inc.

Consolidated Balance Sheet s

(in thousands, except share and per share information)

(unaudited)

 

 

 

 

 

 

 

 

 

 

    

September 30,

    

December 31,

 

 

2014

 

2013

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Accounts receivable, less allowance for doubtful accounts of  $1,985 at September 30, 2014 and $2,185 at December 31, 2013

 

$

67,342 

 

$

69,667 

Inventories

 

 

9,761 

 

 

9,481 

Deferred income taxes, net

 

 

1,494 

 

 

1,841 

Other current assets

 

 

6,546 

 

 

4,438 

Total current assets

 

 

85,143 

 

 

85,427 

 

 

 

 

 

 

 

Property and equipment:

 

 

 

 

 

 

Medical equipment

 

 

585,933 

 

 

584,078 

Property and office equipment

 

 

83,294 

 

 

80,696 

Accumulated depreciation

 

 

(434,717)

 

 

(405,443)

Total property and equipment, net

 

 

234,510 

 

 

259,331 

 

 

 

 

 

 

 

Other long-term assets:

 

 

 

 

 

 

Goodwill

 

 

335,577 

 

 

335,577 

Other intangibles, net

 

 

176,016 

 

 

220,631 

Other, primarily deferred financing costs, net

 

 

12,852 

 

 

14,649 

Total assets

 

$

844,098 

 

$

915,615 

 

 

 

 

 

 

 

Liabilities and (Deficit) Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Current portion of long-term debt

 

$

5,777 

 

$

6,487 

Book overdrafts

 

 

4,923 

 

 

9,469 

Accounts payable

 

 

30,041 

 

 

32,502 

Accrued compensation

 

 

15,457 

 

 

11,714 

Accrued interest

 

 

6,562 

 

 

18,884 

Dividend payable

 

 

50 

 

 

73 

Other accrued expenses

 

 

11,226 

 

 

11,031 

Total current liabilities

 

 

74,036 

 

 

90,160 

 

 

 

 

 

 

 

Long-term debt, less current portion

 

 

715,851 

 

 

704,284 

Pension and other long-term liabilities

 

 

6,535 

 

 

7,425 

Payable to Parent

 

 

23,420 

 

 

22,669 

Deferred income taxes, net

 

 

54,165 

 

 

68,057 

 

 

 

 

 

 

 

Commitments and contingencies (Note 9)

 

 

 

 

 

 

 

 

 

 

 

 

 

(Deficit) Equity

 

 

 

 

 

 

Common stock, $0.01 par value; 1,000 shares authorized, issued and outstanding at September 30, 2014 and December 31, 2013

 

 

 —

 

 

 —

Additional paid-in capital

 

 

214,494 

 

 

214,505 

Accumulated deficit

 

 

(240,712)

 

 

(187,901)

Accumulated other comprehensive loss

 

 

(3,884)

 

 

(3,884)

Total Universal Hospital Services, Inc. (deficit) equity

 

 

(30,102)

 

 

22,720 

Noncontrolling interest

 

 

193 

 

 

300 

Total (deficit) equity

 

 

(29,909)

 

 

23,020 

Total liabilities and (deficit) equity

 

$

844,098 

 

$

915,615 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

2


 

Table of Contents

 

Universal Hospital Services,   Inc.

Consolidated Statements of Operation s

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

 

    

2014

    

2013

    

2014

    

2013

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Medical equipment solutions

 

$

67,861 

 

$

68,355 

 

$

216,771 

 

$

215,141 

Clinical engineering solutions

 

 

23,717 

 

 

21,839 

 

 

68,505 

 

 

65,000 

Surgical services

 

 

14,887 

 

 

14,084 

 

 

43,890 

 

 

41,486 

Total revenues

 

 

106,465 

 

 

104,278 

 

 

329,166 

 

 

321,627 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Cost of medical equipment solutions

 

 

32,204 

 

 

31,107 

 

 

97,919 

 

 

94,918 

Cost of clinical engineering solutions

 

 

18,670 

 

 

16,310 

 

 

54,454 

 

 

50,120 

Cost of surgical services

 

 

7,982 

 

 

7,921 

 

 

24,418 

 

 

23,175 

Medical equipment depreciation

 

 

17,766 

 

 

18,314 

 

 

55,996 

 

 

54,670 

Total costs of revenues

 

 

76,622 

 

 

73,652 

 

 

232,787 

 

 

222,883 

Gross margin

 

 

29,843 

 

 

30,626 

 

 

96,379 

 

 

98,744 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

26,539 

 

 

27,070 

 

 

85,416 

 

 

87,246 

Restructuring, acquisition and integration expenses

 

 

 —

 

 

 —

 

 

1,820 

 

 

236 

Intangible asset impairment charge

 

 

 —

 

 

 —

 

 

34,900 

 

 

 —

Operating income (loss)

 

 

3,304 

 

 

3,556 

 

 

(25,757)

 

 

11,262 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss on extinguishment of debt

 

 

 —

 

 

 —

 

 

 —

 

 

1,853 

Interest expense

 

 

13,264 

 

 

13,834 

 

 

39,922 

 

 

41,657 

Loss before income taxes and noncontrolling interest

 

 

(9,960)

 

 

(10,278)

 

 

(65,679)

 

 

(32,248)

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision (benefit) for income taxes

 

 

225 

 

 

(1,313)

 

 

(13,232)

 

 

(398)

Consolidated net loss

 

 

(10,185)

 

 

(8,965)

 

 

(52,447)

 

 

(31,850)

Net income attributable to noncontrolling interest

 

 

103 

 

 

216 

 

 

364 

 

 

532 

Net loss attributable to Universal Hospital Services, Inc.

 

$

(10,288)

 

$

(9,181)

 

$

(52,811)

 

$

(32,382)

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

Universal Hospital Services,   Inc.

Consolidated Statements of Comprehensive Los s

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

 

    

2014

    

2013

    

2014

    

2013

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated net loss

 

$

(10,185)

 

$

(8,965)

 

$

(52,447)

 

$

(31,850)

Total other comprehensive income

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Comprehensive loss

 

 

(10,185)

 

 

(8,965)

 

 

(52,447)

 

 

(31,850)

Comprehensive income attributable to noncontrolling interest

 

 

103 

 

 

216 

 

 

364 

 

 

532 

Comprehensive loss attributable to Universal Hospital Services, Inc.

 

$

(10,288)

 

$

(9,181)

 

$

(52,811)

 

$

(32,382)

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

3


 

Table of Contents

Universal Hospital Services, Inc.

Consolidated Statements of Cash Flow s

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

September 30,

 

    

2014

    

2013

Cash flows from operating activities:

 

 

 

 

 

 

Consolidated net loss

 

$

(52,447)

 

$

(31,850)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

 

 

Depreciation

 

 

64,120 

 

 

63,157 

Assets impairment charges

 

 

2,025 

 

 

 —

Intangible asset impairment charge

 

 

34,900 

 

 

 —

Amortization of intangibles, deferred financing costs and bond premium

 

 

10,359 

 

 

12,017 

Non-cash write off of deferred financing cost

 

 

 —

 

 

1,853 

Provision for doubtful accounts

 

 

658 

 

 

1,216 

Provision for inventory obsolescence

 

 

(27)

 

 

22 

Non-cash share-based compensation expense - net

 

 

801 

 

 

609 

Gain on sales and disposals of equipment

 

 

(1,791)

 

 

(1,070)

Deferred income taxes

 

 

(13,545)

 

 

733 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

1,667 

 

 

75 

Inventories

 

 

(253)

 

 

(989)

Other operating assets

 

 

(2,137)

 

 

(199)

Accounts payable

 

 

221 

 

 

(755)

Other operating liabilities

 

 

(9,274)

 

 

(9,341)

Net cash provided by operating activities

 

 

35,277 

 

 

35,478 

Cash flows from investing activities:

 

 

 

 

 

 

Medical equipment purchases

 

 

(44,563)

 

 

(39,799)

Property and office equipment purchases

 

 

(3,610)

 

 

(6,327)

Proceeds from disposition of property and equipment

 

 

6,996 

 

 

2,632 

Purchases of noncontrolling interests

 

 

(46)

 

 

 —

Holdback payment related to acquisition

 

 

 —

 

 

(1,655)

Net cash used in investing activities

 

 

(41,223)

 

 

(45,149)

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds under senior secured credit facility

 

 

123,400 

 

 

82,900 

Payments under senior secured credit facility

 

 

(107,200)

 

 

(66,700)

Payments of principal under capital lease obligations

 

 

(5,199)

 

 

(5,679)

Payments of floating rate notes

 

 

 —

 

 

(230,000)

Proceeds from issuance of bonds

 

 

 —

 

 

234,025 

Accrued interest received from bondholders

 

 

 —

 

 

8,620 

Accrued interest paid to bondholders

 

 

 —

 

 

(8,620)

Distributions to noncontrolling interests

 

 

(436)

 

 

(528)

Dividend and equity distribution payments

 

 

(73)

 

 

 —

Payment of deferred financing costs

 

 

 —

 

 

(4,116)

Change in book overdrafts

 

 

(4,546)

 

 

(231)

Net cash provided by financing activities

 

 

5,946 

 

 

9,671 

Net change in cash and cash equivalents

 

 

 —

 

 

 —

 

 

 

 

 

 

 

Cash and cash equivalents at the beginning of period

 

 

 —

 

 

 —

Cash and cash equivalents at the end of period

 

$

 —

 

$

 —

 

 

 

 

 

 

 

Supplemental cash flow information:

 

 

 

 

 

 

Interest paid

 

$

51,528 

 

$

47,296 

Income taxes paid

 

 

318 

 

 

320 

Non-cash activities:

 

 

 

 

 

 

Medical equipment purchases included in accounts payable (at end of period)

 

$

10,973 

 

$

6,894 

Capital lease additions

 

 

1,038 

 

 

9,174 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

4


 

Table of Contents

Universal Hospital Services,   Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

1. Basis of Presentation

 

The interim consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared by Universal Hospital Services, Inc. (“we”, “our”, “us”, the “Company”, or “UHS”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).  Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted, pursuant to such rules and regulations.  These consolidated financial statements should be read in conjunction with the financial statements and related notes included in the Company’s 2013 Annual Report on Form 10-K filed with the SEC.

 

The interim consolidated financial statements presented herein as of September 30, 2014, reflect, in the opinion of management, all adjustments necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented.  These adjustments are all of a normal, recurring nature.  The results of operations for any interim period are not necessarily indicative of results for the full year.

 

We are required to make estimates and assumptions about future events in preparing consolidated financial statements in conformity with GAAP.  These estimates and assumptions affect the amounts of assets, liabilities, revenues and expenses at the date of the unaudited consolidated financial statements.  While we believe that our past estimates and assumptions have been materially accurate, our current estimates are subject to change if different assumptions as to the outcome of future events are made.  We evaluate our estimates and judgments on an ongoing basis and predicate those estimates and judgments on historical experience and on various other factors that we believe to be reasonable under the circumstances.  We make adjustments to our assumptions and judgments when facts and circumstances dictate.  Since future events and their effects cannot be determined with absolute certainty, actual results may differ from the estimates used in preparing the accompanying unaudited consolidated financial statements.

 

A description of our significant accounting policies is included in our 2013 Annual Report on Form 10-K. There have been no material changes to these policies for the quarter ended September 30, 2014.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of UHS and its 100%-owned subsidiary, UHS Surgical Services, Inc. (“Surgical Services”). In addition, in accordance with guidance issued by the Financial Accounting Standards Board (“FASB”), we have accounted for our equity investments in entities in which we are the primary beneficiary under the full consolidation method. All significant intercompany transactions and balances have been eliminated through consolidation. As the primary beneficiary, we consolidate the limited liability companies (“LLCs”) referred to in Note 11, Limited Liability Companies, as we effectively receive the majority of the benefits from such entities and we provide equipment lease guarantees for such entities.

 

Reclassifications

 

Certain amounts in the 2013 Consolidated Statements of Operations have been reclassified to conform with the 2014 presentation.

 

2. Recent Accounting Pronouncements

 

Standard Adopted

 

In July 2013, the FASB issued Accounting Standards Update (“ASU”) No. 2013-11 Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist (“ASU 2013-11”). ASU 2013-11 requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss (“NOL”) carryforward, or similar tax loss or tax credit

5


 

Table of Contents

carryforward, rather than as a liability when (1) the uncertain tax position would reduce the NOL or other carryforward under the tax law of the applicable jurisdiction and (2) the entity intends to use the deferred tax asset for that purpose. The ASU does not require new   recurring disclosures. ASU 2013-11 is effective prospectively for fiscal years beginning after December 15, 2013 and interim periods within those years. The adoption of ASU 2013-11 did not have a material effect on our consolidated financial statements.

 

Standard s Not Yet Adopted

 

In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (“ASU 2014-09”), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in the U.S. GAAP when it becomes effective. The new standard is effective beginning after December 15, 2016 and interim periods within those years. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting .

 

In August 2014, the FASB issued ASU No. 2014-15 Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties a bout an Entity’s Ability to Continue as a Going Concern  (“ASU 2014-15”), which requires management to evaluate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern and whether or not it is probable that the entity will be unable to meet its obligations as they become due within one year after the date the financial statements are issued. The new standard is effective beginning after December 15, 2016 and interim periods within those years. Early adoption is permitted. We are evaluating the effect that ASU 2014-15 will have on our consolidated financial statements and related disclosures.

 

3. Fair Value Measurements

 

Financial assets and liabilities measured at fair value on a recurring basis as of September 30 , 2014 and December 31, 2013 are summarized in the following table by type of inputs applicable to the fair value measurements:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value at September 30, 2014

 

Fair Value at December 31, 2013

(in thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

    

Level 1

    

Level 2

    

Level 3

    

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contingent Consideration

 

$

 —

 

$

 —

 

$

158 

 

$

158 

 

$

 —

 

$

 —

 

$

215 

 

$

215 

 

A description of the inputs used in the valuation of assets and liabilities is summarized as follows:

 

Level 1 — Inputs represent unadjusted quoted prices for identical assets or liabilities exchanged in active markets.

 

Level 2 — Inputs include directly or indirectly observable inputs other than Level 1 inputs such as quoted prices for similar assets or liabilities exchanged in active or inactive markets; quoted prices for identical assets or liabilities exchanged in inactive markets; other inputs that are considered in fair value determinations of the assets or liabilities, such as interest rates and yield curves that are observable at commonly quoted intervals, volatilities, prepayment speeds, loss severities, credit risks and default rates; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

Level 3 — Inputs include unobservable inputs used in the measurement of assets and liabilities. Management is required to use its own assumptions regarding unobservable inputs because there is little, if any, market activity in the assets or liabilities or related observable inputs that can be corroborated at the measurement date. Measurements of non-exchange traded derivative contract assets and liabilities are primarily based on valuation models, discounted cash flow models or other valuation techniques that are believed to be used by market participants. Unobservable inputs require management to make certain projections and assumptions about the information that would be used by market participants in pricing assets or liabilities.

 

During 2012, we recorded a contingent consideration liability, in the form of an earn-out payment, related to our acquisitions. The contingent consideration payments are based on achieving certain revenue results. The fair value of the

6


 

Table of Contents

liability was estimated using a discounted cash flow approach with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement .   The significant inputs in the Level 3 measurement not supported by market activity included our assessments of expected future cash flows during the earn-out period, related to the assets acquired, appropriately discounted considering the uncertainties associated with the obligation, and calculated based on estimated revenues in accordance with the terms of the agreement. During the three months ended September 30 , 2014 and 2013 , we paid $0.0 2 and $0.02 million , respectively, in earn-out s.  During the nine months ended September 30, 2014 and 2013, we paid   $0.0 6 and $0.0 7 million, respectively, in earn-outs.

 

The assumptions used in preparing the discounted cash flow analysis included estimates of interest rates and the timing and amount of incremental cash flows.

 

A reconciliation of the beginning and ending balance for the Level 3 measurement are as follows:

 

 

 

 

 

 

(in thousands)

    

    

 

Balance at December 31, 2013

 

$

215 

Payments

 

 

(57)

Balance at September 30, 2014

 

$

158 

 

During the three and nine months ended September  3 0 , 2014, we recorded $0 and  $ 2.0 million , respectively, of impairment charge on certain long-lived assets for which the carrying value of those assets may not be recoverable based upon our estimated cash flows. The fair value of the assets was estimated using a discounted cash flow approach with significant inputs that are not observable i n the market and thus represents a Level 3 fair value measurement.  There w ere no assets impairment s for the three and nine months ended September 30 , 2013. The fair value of those assets measured on a nonrecurring basis was $ 0 million as of September 30 , 2014 .

 

During the three and nine months ended September 30 , 2014, we recorded $0 and $34.9 million of int angible asset impairment charge.   The fair value of the intangible asset was estimated using an income approach with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement. There were no intangible asset impairment charges for the three and nine months ended September 30 , 2013. Intangible asset impairment charge recorded during the second quarter of 2014 is discussed in Note 4, Goodwill and Other Intangible Assets.

 

Fair Value of Other Financial Instruments

 

The Company considers that the carrying amount of financial instruments, including accounts receivable, accounts payable, accrued liabilities and senior secured credit facility, approximates fair value due to their short maturities. The fair value of our outstanding Original Notes and Add-on Notes (each as defined in Note 8, Long-Term Debt) as of September 30 , 2014 and December 31, 2013, based on the quoted market price for the same or similar issues of debt, which represents a Level 2 fair value measurement, is approximately:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30, 2014

 

December 31, 2013

 

    

Carrying

    

Fair

    

Carrying

    

Fair

(in millions)

 

Value

 

Value

 

Value

 

Value

 

 

 

 

 

 

 

 

 

 

 

 

 

Original notes - 7.625%

 

$

425.0 

 

$

399.5 

 

$

425.0 

 

$

450.5 

Add-on notes - 7.625% (1)

 

 

231.5 

 

 

206.8 

 

 

232.7 

 

 

233.2 

(1) The carrying value of the Add-on notes - 7.625% includes unamortized bond premium of $1 1.5 and $12.7 million as of September 30 , 2014 and December 31, 2013, respectively.

 

 

7


 

Table of Contents

4. Goodwill and Other Intangible Assets

 

Our goodwill as of September 30, 2014 and December 31, 2013, by reporting segment, consists of the following:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

Medical

    

Clinical

    

    

    

    

 

 

 

Equipment

 

Engineering

 

Surgical

 

 

 

(in thousands)

 

Solutions

 

Solutions

 

Services

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2013

 

$

227,486 

 

$

55,655 

 

$

52,436 

 

$

335,577 

Acquisitions

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Balance at September 30, 2014

 

$

227,486 

 

$

55,655 

 

$

52,436 

 

$

335,577 

 

Our other intangible assets as of September 30, 2014 and December 31, 2013 consist of the following:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30, 2014

 

December 31, 2013

 

    

    

    

Accumulated

    

 

    

    

    

    

    

Accumulated

    

 

    

    

(in thousands)

 

Cost

 

Amortization

 

Impairment

 

Net

 

Cost

 

Amortization

 

Impairment

 

Net

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Finite-life intangibles

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer relationship

 

$

115,731 

 

$

(78,358)

 

$

 —

 

$

37,373 

 

$

115,731 

 

$

(70,964)

 

$

 —

 

$

44,767 

Supply agreement

 

 

26,000 

 

 

(18,738)

 

 

 —

 

 

7,262 

 

 

26,000 

 

 

(16,560)

 

 

 —

 

 

9,440 

Technology databases

 

 

7,217 

 

 

(7,217)

 

 

 —

 

 

 —

 

 

7,217 

 

 

(7,199)

 

 

 —

 

 

18 

Non-compete agreements

 

 

780 

 

 

(499)

 

 

 —

 

 

281 

 

 

780 

 

 

(374)

 

 

 —

 

 

406 

Favorable lease agreements

 

 

134 

 

 

(134)

 

 

 —

 

 

 —

 

 

134 

 

 

(134)

 

 

 —

 

 

 —

Total finite-life intangibles

 

 

149,862 

 

 

(104,946)

 

 

 —

 

 

44,916 

 

 

149,862 

 

 

(95,231)

 

 

 —

 

 

54,631 

Indefinite-life intangibles

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade names

 

 

166,000 

 

 

 —

 

 

(34,900)

 

 

131,100 

 

 

166,000 

 

 

 —

 

 

 —

 

 

166,000 

Total intangible assets

 

$

315,862 

 

$

(104,946)

 

$

(34,900)

 

$

176,016 

 

$

315,862 

 

$

(95,231)

 

$

 —

 

$

220,631 

 

During the second quarter of 2014, the Company became aware of certain events that will have a negative impact on the future financial results of the Company. The Company applies a fair value based impairment test to the net book value of goodwill and intangible assets with indefinite lives on an annual basis and on an interim basis if events or circumstances indicate that an impairment loss may have occurred. The review of indefinite-life intangibles for impairment during the second quarter of 2014 indicated that the carrying value of trade names in the MES segment exceeded its estimated fair values. The Company performed an interim impairment test and recorded a non-cash impairment charge of $34.9 million in the second quarter of 2014. As a result of the trade names impairment, the Company’s equity went to a deficit causing the Company to undertake a step 2 goodwill impairment analysis. The preliminary step 2 analysis of the MES goodwill reflects no impairment, and therefore none has been recorded in the second quarter of 2014. The calculation of the preliminary step 2 goodwill analysis contain ed significant judgments and estimates including weighted average cost of capital, future revenue, profitability, cash flows and fair values of assets and liabilities. The finalization of the step 2 analysis and the result of the third quarter impairment review resulted in no changes to or additional impairment charge s .   There were no impairment charges during the three and nine months ended September 30, 2013 with respect to trade names.

 

Total amortization expense related to intangible assets were $3.1 and $3.4 million for the three months ended September 30, 2014 and 2013, respectively and $9.7 and $10.4 million for the nine months ended September 30, 2014 and 2013, respectively.

 

8


 

Table of Contents

The estimated future amortization expense for identifiable intangible assets during the remainder of 2014 and the next five years is as follows:

 

 

 

 

 

 

(in thousands)

    

    

 

 

 

 

 

Remainder of 2014

 

$

3,110 

2015

 

 

11,931 

2016

 

 

10,807 

2017

 

 

7,514 

2018

 

 

5,931 

2019

 

 

3,364 

 

 

 

 

 

 

5. Equit y (Deficit)

 

The following tables represent changes in equity (deficit) that are attributable to our shareholders and noncontrolling interests for the nine month periods ended September 30 , 2014 and 2013.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

    

    

    

 

    

Accumulated

    

    

 

    

    

 

 

 

Additional

 

 

 

 

Other

 

 

 

 

Total

 

 

Paid-in

 

Accumulated

 

Comprehensive

 

Noncontrolling

 

Equity

(in thousands)

 

Capital

 

Deficit

 

Loss

 

Interests

 

(Deficit)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2013

 

$

214,505 

 

$

(187,901)

 

$

(3,884)

 

$

300 

 

$

23,020 

Net (loss) income

 

 

 —

 

 

(52,811)

 

 

 —

 

 

364 

 

 

(52,447)

Cash distributions to noncontrolling interests

 

 

 —

 

 

 —

 

 

 —

 

 

(436)

 

 

(436)

Purchases of noncontrolling interests

 

 

(11)

 

 

 —

 

 

 —

 

 

(35)

 

 

(46)

Balance at September 30, 2014

 

$

214,494 

 

$

(240,712)

 

$

(3,884)

 

$

193 

 

$

(29,909)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

    

    

    

 

    

Accumulated

    

    

 

    

    

 

 

 

Additional

 

 

 

 

Other

 

 

 

 

 

 

 

 

Paid-in

 

Accumulated

 

Comprehensive

 

Noncontrolling

 

Total

(in thousands)

 

Capital

 

Deficit

 

Loss

 

Interests

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2012

 

$

214,481 

 

$

(144,864)

 

$

(9,086)

 

$

344 

 

$

60,875 

Net (loss) income

 

 

 —

 

 

(32,382)

 

 

 —

 

 

532 

 

 

(31,850)

Cash distributions to noncontrolling interests

 

 

 —

 

 

 —

 

 

 —

 

 

(528)

 

 

(528)

Balance at September 30, 2013

 

$

214,481 

 

$

(177,246)

 

$

(9,086)

 

$

348 

 

$

28,497 

 

 

 

 

 

9


 

Table of Contents

6. Share-Based Compensation

 

During the nin e months ended September 30 , 2014, activity under the 2007 Stock Option Plan (the “2007 Stock Option Plan”), of UHS Holdco, Inc., our parent company (“Parent”), was as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

    

 

 

    

 

 

    

Weighted

 

 

 

 

 

 

 

 

 

 

average

 

 

 

 

Weighted

 

 

 

 

remaining

 

 

 

 

average

 

Aggregate

 

contractual

(in thousands except exercise price and years)

 

Number of Options

 

exercise price

 

intrinsic value

 

term (years)

 

 

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2013

 

38,116 

 

$

1.17 

 

$

9,611 

 

5.5 

Granted

 

 —

 

 

 

 

 

 

 

Exercised

 

 —

 

 

 

 

 

 

 

Forfeited or expired

 

(3,749)

 

 

1.38 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at September 30, 2014

 

34,367 

 

$

1.15 

 

$

9,478 

 

4.4 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at September 30, 2014

 

26,764 

 

$

1.07 

 

$

9,444 

 

3.3 

 

 

 

 

 

 

 

 

 

 

 

Remaining authorized options available for issue

 

9,319 

 

 

 

 

 

 

 

 

 

The exercise price of the stock option award is equal to the market value of Parent’s common stock on the grant date as determined reasonably and in good faith by Parent’s Board of Directors and compensation committee and based on an analysis of a variety of factors including peer group multiples, merger and acquisition multiples, and discounted cash flow analyses.

 

The intrinsic value of a stock award is the amount by which the market value of the underlying stock exceeds the exercise price of the award.

 

We determine the fair value of stock options using the Black-Scholes option pricing model. The estimated fair value of options, including the effect of estimated forfeitures, is recognized as expense on a straight-line basis over the options’ expected vesting periods. There were no stock options granted during the nine months ended September 30 , 2014.

 

Although Parent grants stock options, the Company recognizes compensation expense related to these options since the services are performed for its benefit.  Along with this expense, which is primarily included in Selling, General and Administrative expense, the Company records an offsetting Payable to Parent liability which is not expected to be settled within the next twelve months.

 

At September 30 , 2014, unearned non-cash share-based compensation that we expect to recognize as expense over a weighted average period of 1.9 years totals approximately $ 3. 2 million, net of our estimated forfeiture rate of 2.0%. The expense could be accelerated upon the sale of Parent or the Company.

 

7. Dividend and Equity Distribution

 

On June 8, 2011, the Board of Directors declared an equity distribution of $0.12 per option to holders of outstanding options on the Parent’s stock on June 10, 2011 that vested on December 31, 2011, 2012 and 2013 and are scheduled to vest on December 31, 2014 and 2015.

 

Our consolidated balance sheets as of September 30 , 2014 and December 31, 2013 reflect the related current dividend payable and long-term dividend payable included in Payable to Parent for estimated amounts to be paid to holders of options expected to vest on December 31, 2014 through 2015 based on an estimated option forfeiture rate of 2% annually.

 

10


 

Table of Contents

8. Long-Term Debt

 

Long-term debt consists of the following:

 

 

 

 

 

 

 

 

 

 

    

September 30,

    

December 31,

(in thousands)

 

2014

 

2013

Original notes - 7.625%

 

$

425,000 

 

$

425,000 

Add-on notes - 7.625%

 

 

220,000 

 

 

220,000 

Unamortized bond premium

 

 

11,520 

 

 

12,702 

Senior secured credit facility

 

 

49,200 

 

 

33,000 

Capital lease obligations

 

 

15,908 

 

 

20,069 

 

 

 

721,628 

 

 

710,771 

Less: Current portion of long-term debt

 

 

(5,777)

 

 

(6,487)

Total long-term debt

 

$

715,851 

 

$

704,284 

 

Original Notes and Add-on Notes — 7.625%. On August 7, 2012, we issued $425.0 million in aggregate principal amount of 7.625% Second Lien Senior Secured Notes due 2020 (the “Original Notes”) under an indenture dated as of August 7, 2012 (the “2012 Indenture”). On February 12, 2013, we issued $220.0 million in aggregate principal amount of 7.625% Second Lien Senior Secured Notes due 2020 (the “Add-on Notes”, and along with the Original Notes, the “2012 Notes”) as “additional notes” pursuant to the 2012 Indenture . The 2012 Notes mature on August 15, 2020.

 

The 2012 Indenture provides that the 2012 Notes are our second lien senior secured obligations and are fully and unconditionally guaranteed on a second lien senior secured basis by our existing and certain of our future 100%-owned domestic subsidiaries.

 

Interest on the 2012 Notes is payable, entirely in cash, semiannually, in arrears, on February 15 and August 15 of each year, beginning on February 15, 2013. We may redeem some or all of the 2012 Notes at the redemption prices set forth in the 2012 Indenture.  If we sell certain assets or undergo certain kinds of changes of control, we must offer to repurchase the 2012 Notes.  

 

Our 2012 Notes are subject to certain debt covenants which are described below under the heading “2012 Indenture” .

 

In connection with the issuance of the 2012 Notes, we entered into a registration rights agreement with the initial purchasers of the 2012 Notes.  Pursuant to those agreements, we filed Registration Statements on Form S-4 to register the exchanges of the 2012 Notes for fully registered 2012 Notes. Following declaration of effective ness by the SEC, we completed offers to exchange all of the then outstanding 2012 Notes for an equivalent amount of the 2012 Notes which have been registered under the Securities Act of 1933, as amended. We did not receive any additional proceeds from the exchange offers.

 

Senior Secured Credit Facility.  On July 31, 2012, we entered into a Second Amended and Restated Credit Agreement with Bank of America, N.A., as agent for the lenders, and the lenders party thereto (the “Second Amended Credit Agreement”), which amended our then-existing senior secured credit facility originally dated as of May 31, 2007 and amended and restated as of May 6, 2010. We refer to the second amended and restated senior secured credit facility as the “senior secured credit facility.” The senior secured credit facility is a first lien senior secured asset based revolving credit facility that is available for working capital and general corporate purposes, including permitted investments, capital expenditures and debt repayments, on a fully revolving basis, subject to the terms and conditions set forth in the credit documents in the form of revolving loans, swing line loans and letters of credit. The Second Amended Credit Agreement increased the aggregate amount we may obtain under revolving loans from $195.0 million to $235.0 million and extended the maturity date to July 31, 2017.  Our obligations under the Second Amended Credit Agreement are secured by a first priority security interest in substantially all of our assets, excluding a pledge of our and Parent’s stock, any joint ventures and certain other exceptions.  Our obligations under the Second Amended Credit Agreement are unconditionally guaranteed by P arent and our restricted subsidiaries.

 

11


 

Table of Contents

As of September 30 , 2014, we had $129.4 million of availability under the senior secured credit facility based on a borrowing base of $182.2 million less borrowings of $ 49.2 million and after giving effect to $ 3.6 million used for letters of credit.

 

The senior secured credit facility requires our compliance with various affirmative and negative covenants. Pursuant to the affirmative covenants, we and Parent agreed to, among other things, deliver financial and other information to the administrative agent, provide notice of certain events (including events of default), pay our obligations, maintain our properties, maintain the security interest in the collateral for the benefit of the administrative agent and the lenders and maintain insurance.

 

Among other restrictions, and subject to certain definitions and exceptions, the senior secured credit facility restricts our ability to:

 

·

incur indebtedness;

·

create or permit liens;

·

declare or pay dividends and certain other restricted payments;

·

consolidate, merge or recapitalize;

·

acquire or sell assets;

·

make certain investments, loans or other advances;

·

enter into transactions with affiliates;

·

change our line of business; and

·

enter into hedging transactions.

 

The senior secured credit facility also contains a financial covenant that is triggered if our available borrowing capacity is less than $20.0 million for a certain period, which consists of a minimum ratio of trailing four-quarter Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) to cash interest expense, as such terms are defined in the senior secured credit facility.

 

The senior secured credit facility specifies certain events of default, including, among others, failure to pay principal, interest or fees, violation of covenants, inaccuracy of representations or warranties, bankruptcy events, certain ERISA-related events, cross-defaults to other material agreements, change of control events and invalidity of guarantees or security documents Some events of default will be triggered only after certain cure periods have expired, or will provide for materiality thresholds.  If such a default occurs, the lenders under the senior secured credit facility would be entitled to take various actions, including all actions permitted to be taken by a secured creditor and the acceleration of amounts due under the senior secured credit facility.

 

Borrowings under the senior secured credit facility accrue interest (including a credit spread varying with facility usage):

 

·

at a per annum rate equal to 1.00% - 1.50% above the rate equal to the greater of (i) the “federal funds rate” plus one-half of one percent (0.50%) per annum, (ii) the “prime rate” announced from time to time by the administrative agent for such day and (iii) the “Eurodollar rate” for a one month interest period as determined on such day, plus one percent (1.0%) payable quarterly in arrears; and

 

·

at a per annum rate equal to 2.00% - 2.50% above the adjusted British Bankers Association Interest Settlement Rate for deposits in Dollars rate used by the administrative agent with a term equivalent to the selected interest rate period, for the respective interest rate period determined at our option, payable in arrears upon cessation of the interest rate period elected, provided that for an interest rate period longer than three months, payable in arrears on the respective dates that fall every three months from the beginning of such interest rate period.

 

At September 30 , 2014, we had $ 49.2 million of borrowings outstanding of which $ 44 .0 million was accruing interest at a rate of 2. 6536 %,   $3.0 million was accruing interest at a rate of 2.6535% and $2 .2 million was accruing interest at a rate of 4 . 75 % .

 

We were in compliance with all financial debt covenants for all periods presented.

 

12


 

Table of Contents

2012 Indenture. Our 2012 Notes are guaranteed, jointly and severally, on a second priority senior secured basis, by Surgical Services, and are also similarly guaranteed by certain of our future 100%-owned domestic subsidiaries. The 2012 Notes are our second priority senior secured obligations and rank (i) equal in right of payment with all of our existing and future unsubordinated indebtedness, and effectively senior to any such unsecured indebtedness to the extent of the value of collateral; (ii) senior in right of payment to all of our and our guarantors’ existing and future subordinated indebtedness; (iii) effectively junior to our senior secured credit facility; and (iv) structurally subordinated to any indebtedness and other liabilities (including trade payables) of any of our future subsidiaries that are not guarantors.

 

The 2012 Indenture governing the 2012 Notes contains covenants that limit our and our guarantors’ ability, subject to certain definitions and exceptions, and certain of our future subsidiaries’ ability to:

 

·

incur additional indebtedness;

·

pay cash dividends or distributions on our capital stock or repurchase our capital stock or subordinated debt;

·

issue redeemable stock or preferred stock;

·

issue stock of subsidiaries;

·

make certain investments;

·

transfer or sell assets;

·

create liens on our assets to secure debt;

·

enter into transactions with affiliates; and

·

merge or consolidate with another company.

 

The 2012 Indenture specifies certain events of default, including among others, failure to pay principal, interest or premium, violation of covenants and agreements, cross-defaults to other material agreements, bankruptcy events, invalidity of guarantees, and a default in the performance by us of the security documents relating to the 2012 Indenture. Some events of default will be triggered only after certain grace or cure periods have expired, or provide for materiality thresholds. In the event certain bankruptcy-related defaults occur, the 2012 Notes will become due and payable immediately. If any other default occurs, the Trustee (and in some cases the noteholders) would be entitled to take various actions, including acceleration of amounts due under the 2012 Indenture.

 

We were in compliance with all financial debt covenants for all periods presented.

 

9. Commitments and Contingencies

 

The Company, in the ordinary course of business, could be subject to liability claims related to employees and the equipment that it rents and services. Asserted claims are subject to many uncertainties and the outcome of individual matters is not predictable. While the ultimate resolution of these actions may have an impact on the Company’s financial results for a particular reporting period, management believes that any such resolution would not have a material adverse effect on the financial position, results of operations or cash flows of the Company and the chance of a negative outcome on outstanding litigation is considered remote.

 

10. Related Party Transactions

 

Management Agreement

 

On May 31, 2007, we and Irving Place Capital Merchant Manager III, L.P. (“IPC”) entered into a professional services agreement pursuant to which IPC provides general advisory and management services to us with respect to financial and operating matters.  IPC is a principal owner of Parent, and the following members of our board of directors are associated with IPC:  Michael Feiner, Robert Juneja, and Bret Bowerman. In addition, David Crane, a director, provides certain services to IPC. The professional services agreement requires us to pay an annual fee for ongoing advisory and management services equal to the greater of $0.5 million or 0.75% of our Adjusted EBITDA (as defined in the professional services agreement) for the immediately preceding fiscal year, payable in quarterly installments. The professional services agreement provides that IPC will be reimbursed for its reasonable out-of-pocket expenses in connection with certain activities undertaken pursuant to the professional services agreement and will be indemnified for liabilities incurred in connection with its role under the professional services agreement, other than for liabilities resulting from its gross negligence or willful misconduct. The term of the professional services agreement commenced on May 31, 2007 and will remain in effect unless and until either party notifies the other of its desire to terminate, we are

13


 

Table of Contents

sold to a third-party purchaser or we consummate a qualified initial public offering, as defined in the professional services agreement. Total professional services fees incurred to IPC were $0.3 and $0.3 million for the three month periods ended September 30 , 2014 and 2013, respectively ,   and $0. 7 and $0. 8 million for the nine month periods ended September 30 , 2014 and 2013, respectively .

 

Business Relationship

 

In the ordinary course of business, we entered into an operating lease for our Minneapolis, Minnesota district service center with Ryan Fund V, LLC (“Ryan”), which began on May 1, 2007.  One member of our board of directors is also a limited partner in Ryan which has ownership interest in an LLC that owns the property. Total rent expense to Ryan were $0.1 and $0.1 million during the three month periods ended September 30 , 2014 and 2013, respectively ,   and $0. 3 and $0. 3 million during the nine month periods ended September 30 , 2014 and 2013, respectively.

 

In the ordinary course of business, we entered into engagement letters with CTPartners, LLC (“CTPartners”) during 2012 through 2014 to conduct searches for certain executive positions.  One member of our board of directors is also a director of CTPartners. Total fees incurred to CTPartners was $0 .1 and $0 million for the three month periods ended September 30 , 2014 and 2013 , respectively, and $0. 3 and $0.2 million during the nine month periods ended September 30 , 2014 and 2013, respectively .

 

The Company believes that the aforementioned arrangements and relationships were provided in the ordinary course of business.

 

11. Limited Liability Companies

 

We participate with others in the formation of LLCs in which Surgical Services becomes a partner and shares the financial interest with the other investors. Surgical Services is the primary beneficiary of these LLCs. These LLCs acquire certain medical equipment for use in their respective business activities, which generally focus on surgical procedures. The LLCs will acquire medical equipment for rental purposes under equipment financing leases. At September 30 , 2014, the LLCs had approximately $0. 4 million of total assets. The third party investors in each respective LLC generally provide the lease financing company with individual proportionate lease guarantees based on their respective ownership percentages in the LLCs. In addition, Surgical Services will provide such financing companies with its corporate guarantee based on its respective ownership interest in each LLC. In certain instances, Surgical Services has provided such financing companies with an overall corporate guarantee in connection with equipment financing transactions. In such instances, the individual investors in each respective LLC will generally indemnify us against losses, if any, incurred in connection with its corporate guarantee. Additionally, we provide operational and administrative support to the LLCs in which it is a partner. As of September 30 , 2014, we held interests in six active LLCs.

 

In accordance with guidance issued by the FASB, we account for equity investments in LLCs (in which we are the primary beneficiary) under the full consolidation method whereby transactions between Surgical Services and the LLCs have been eliminated through consolidation.

 

14


 

Table of Contents

12. Segment Information

 

Our reporting segments consist of Medical Equipment Solutions (“MES”), Clinical Engineering Solutions (“CES”) and Surgical Services (“SS”). Certain operating information for our segments as well as a reconciliation of total Company gross margin to loss before income taxes and noncontrolling interest was as follows:

 

Medical Equipment Solutions

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

 

    

2014

    

2013

    

2014

    

2013

Revenues

 

$

67,861 

 

$

68,355 

 

$

216,771 

 

$

215,141 

Cost of revenue

 

 

32,204 

 

 

31,107 

 

 

97,919 

 

 

94,918 

Medical equipment depreciation

 

 

16,340 

 

 

17,189 

 

 

51,843 

 

 

50,620 

Gross margin

 

$

19,317 

 

$

20,059 

 

$

67,009 

 

$

69,603 

 

Clinical Engineering Solutions

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

 

    

2014

    

2013

    

2014

    

2013

Revenues

 

$

23,717 

 

$

21,839 

 

$

68,505 

 

$

65,000 

Cost of revenue

 

 

18,670 

 

 

16,310 

 

 

54,454 

 

 

50,120 

Gross margin

 

$

5,047 

 

$

5,529 

 

$

14,051 

 

$

14,880 

 

Surgical Services

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

 

    

2014

    

2013

    

2014

    

2013

Revenues

 

$

14,887 

 

$

14,084 

 

$

43,890 

 

$

41,486 

Cost of revenue

 

 

7,982 

 

 

7,921 

 

 

24,418 

 

 

23,175 

Medical equipment depreciation

 

 

1,426 

 

 

1,125 

 

 

4,153 

 

 

4,050 

Gross margin

 

$

5,479 

 

$

5,038 

 

$

15,319 

 

$

14,261 

 

Total Gross Margin and Reconciliation to Loss Before Income Taxes and Noncontrolling Interest

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

 

    

2014

    

2013

    

2014

    

2013

Total gross margin

 

$

29,843 

 

$

30,626 

 

$

96,379 

 

$

98,744 

Selling, general and administrative

 

 

26,539 

 

 

27,070 

 

 

85,416 

 

 

87,246 

Restructuring, acquisition and integration expenses

 

 

 —

 

 

 —

 

 

1,820 

 

 

236 

Intangible asset impairment charge

 

 

 —

 

 

 —

 

 

34,900 

 

 

 —

Loss on extinguishment of debt

 

 

 —

 

 

 —

 

 

 —

 

 

1,853 

Interest expense

 

 

13,264 

 

 

13,834 

 

 

39,922 

 

 

41,657 

Loss before income taxes and noncontrolling interest

 

$

(9,960)

 

$

(10,278)

 

$

(65,679)

 

$

(32,248)

 

15


 

Table of Contents

Total Assets By Reporting Segment

(in thousands)

 

 

 

 

 

 

 

 

 

 

    

September 30,

    

December 31,

 

 

2014

 

2013

Medical Equipment Solutions

 

$

633,461 

 

$

701,507 

Clinical Engineering Solutions

 

 

111,021 

 

 

112,746 

Surgical Services

 

 

99,616 

 

 

101,362 

Total Company Assets

 

$

844,098 

 

$

915,615 

 

The following table provides additional detail on percentage of revenue for each group of similar products sold or services provided in the MES, CES and SS segments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2014

 

2013

 

    

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

 

MES

 

 

 

 

 

 

 

 

 

 

Equipment usage solutions

 

59.8 

%  

59.8 

%  

 

61.1 

%  

60.7 

%  

Equipment/disposable sales

 

3.9 

 

5.8 

 

 

4.8 

 

6.2 

 

 

 

63.7 

 

65.6 

 

 

65.9 

 

66.9 

 

CES

 

 

 

 

 

 

 

 

 

 

Service solutions

 

22.3 

 

20.9 

 

 

20.8 

 

20.2 

 

SS

 

 

 

 

 

 

 

 

 

 

Equipment usage solutions

 

13.8 

 

13.4 

 

 

13.1 

 

12.8 

 

Equipment/disposable sales

 

0.2 

 

0.1 

 

 

0.2 

 

0.1 

 

 

 

14.0 

 

13.5 

 

 

13.3 

 

12.9 

 

Total revenues

 

100.0 

%  

100.0 

%  

 

100.0 

%  

100.0 

%  

 

 

 

 

   

13. Income Taxes

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. We evaluate the recoverability of our deferred tax assets by scheduling the expected reversals of deferred tax assets and liabilities in order to determine whether net operating loss carry forwards are recoverable prior to expiration and have established a valuation allowance in accordance with ASC Topic 740 ,   “Income Taxes” . The tax expense for the three   months ended September 30, 2014 primarily relates to state minimum fees. The tax benefit for the nine months ended September 30 , 2014 primarily relates to intangible asset impairment charge, partially offset by state minimum fees. The expected tax benefit from operating loss during the three and nine months ended September 30 , 2014 was offset by the recording of additional valuation allowance. In future reporting periods, we will continue to assess the likelihood that deferred tax assets will be realizable.

 

At September 30 , 2014, the Company had available unused federal net operating loss carryforwards of approximately $207. 3 million. The net operating loss carryforwards will expire at various dates from 2020 through 2035.

 

14. Consolidating Financial Statements

 

In accordance with the provisions of the 2012 Indenture, as a 100%-owned subsidiary of UHS, Surgical Services has jointly and severally guaranteed all the Company’s Obligations (as defined in the 2012 Indenture) on a full and unconditional basis. Consolidating financial information of UHS and the guarantor is presented on the following pages.

 

16


 

Table of Contents

Universal Hospital Services, Inc.

Consolidating Balance Sheets

(in thousands, except share and per share  information)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30, 2014

 

    

Parent

    

Subsidiary

    

    

    

    

 

 

 

Issuer

 

Guarantor

 

Consolidating

 

 

 

 

 

UHS

 

Surgical Services

 

Adjustments

 

Consolidated

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable, less allowance for doubtful accounts

 

$

59,260 

 

$

8,082 

 

$

 —

 

$

67,342 

Due from affiliates

 

 

31,003 

 

 

 —

 

 

(31,003)

 

 

 —

Inventories

 

 

5,310 

 

 

4,451 

 

 

 —

 

 

9,761 

Deferred income taxes, net

 

 

394 

 

 

1,100 

 

 

 —

 

 

1,494 

Other current assets

 

 

6,201 

 

 

345 

 

 

 —

 

 

6,546 

Total current assets

 

 

102,168 

 

 

13,978 

 

 

(31,003)

 

 

85,143 

 

 

 

 

 

 

 

 

 

 

 

 

 

Property and equipment:

 

 

 

 

 

 

 

 

 

 

 

 

Medical equipment

 

 

547,501 

 

 

38,432 

 

 

 —

 

 

585,933 

Property and office equipment

 

 

76,548 

 

 

6,746 

 

 

 —

 

 

83,294 

Accumulated depreciation

 

 

(406,019)

 

 

(28,698)

 

 

 —

 

 

(434,717)

Total property and equipment, net

 

 

218,030 

 

 

16,480 

 

 

 —

 

 

234,510 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other long-term assets:

 

 

 

 

 

 

 

 

 

 

 

 

Goodwill

 

 

283,141 

 

 

52,436 

 

 

 —

 

 

335,577 

Investment in subsidiary

 

 

53,287 

 

 

 —

 

 

(53,287)

 

 

 —

Other intangibles, net

 

 

159,463 

 

 

16,553 

 

 

 —

 

 

176,016 

Other, primarily deferred financing costs, net

 

 

12,683 

 

 

169 

 

 

 —

 

 

12,852 

Total assets

 

$

828,772 

 

$

99,616 

 

$

(84,290)

 

$

844,098 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and (Deficit) Equity

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Current portion of long-term debt

 

$

5,083 

 

$

694 

 

$

 —

 

$

5,777 

Book overdrafts

 

 

4,332 

 

 

591 

 

 

 —

 

 

4,923 

Due to affiliates

 

 

 —

 

 

31,003 

 

 

(31,003)

 

 

 —

Accounts payable

 

 

27,160 

 

 

2,881 

 

 

 —

 

 

30,041 

Accrued compensation

 

 

12,643 

 

 

2,814 

 

 

 —

 

 

15,457 

Accrued interest

 

 

6,562 

 

 

 —

 

 

 —

 

 

6,562 

Dividend payable

 

 

50 

 

 

 —

 

 

 —

 

 

50 

Other accrued expenses

 

 

11,095 

 

 

131 

 

 

 —

 

 

11,226 

Total current liabilities

 

 

66,925 

 

 

38,114 

 

 

(31,003)

 

 

74,036 

 

 

 

 

 

 

 

 

 

 

 

 

 

Long-term debt, less current portion

 

 

714,031 

 

 

1,820 

 

 

 —

 

 

715,851 

Pension and other long-term liabilities

 

 

6,535 

 

 

 —

 

 

 —

 

 

6,535 

Payable to Parent

 

 

23,420 

 

 

 —

 

 

 —

 

 

23,420 

Deferred income taxes, net

 

 

47,952 

 

 

6,213 

 

 

 —

 

 

54,165 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(Deficit) Equity

 

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Additional paid-in capital

 

 

214,505 

 

 

60,008 

 

 

(60,019)

 

 

214,494 

Accumulated deficit

 

 

(233,980)

 

 

(6,732)

 

 

 —

 

 

(240,712)

Accumulated loss in subsidiary

 

 

(6,732)

 

 

 —

 

 

6,732 

 

 

 —

Accumulated other comprehensive loss

 

 

(3,884)

 

 

 —

 

 

 —

 

 

(3,884)

Total Universal Hospital Services, Inc. (deficit) equity

 

 

(30,091)

 

 

53,276 

 

 

(53,287)

 

 

(30,102)

Noncontrolling interest

 

 

 —

 

 

193 

 

 

 —

 

 

193 

Total (deficit) equity

 

 

(30,091)

 

 

53,469 

 

 

(53,287)

 

 

(29,909)

Total liabilities and (deficit) equity

 

$

828,772 

 

$

99,616 

 

$

(84,290)

 

$

844,098 

 

17


 

Table of Contents

Universal Hospital Services, Inc.

Consolidating Balance Sheets

(in thousands, except share and per share  information)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2013

 

    

Parent

    

Subsidiary

    

    

    

    

 

 

 

Issuer

 

Guarantor

 

Consolidating

 

 

 

 

 

UHS

 

Surgical Services

 

Adjustments

 

Consolidated

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable, less allowance for doubtful accounts

 

$

61,709 

 

$

7,958 

 

$

 —

 

$

69,667 

Due from affiliates

 

 

28,299 

 

 

 —

 

 

(28,299)

 

 

 —

Inventories

 

 

5,887 

 

 

3,594 

 

 

 —

 

 

9,481 

Deferred income taxes, net

 

 

1,045 

 

 

796 

 

 

 —

 

 

1,841 

Other current assets

 

 

4,211 

 

 

227 

 

 

 —

 

 

4,438 

Total current assets

 

 

101,151 

 

 

12,575 

 

 

(28,299)

 

 

85,427 

 

 

 

 

 

 

 

 

 

 

 

 

 

Property and equipment:

 

 

 

 

 

 

 

 

 

 

 

 

Medical equipment

 

 

549,306 

 

 

34,772 

 

 

 —

 

 

584,078 

Property and office equipment

 

 

74,336 

 

 

6,360 

 

 

 —

 

 

80,696 

Accumulated depreciation

 

 

(381,387)

 

 

(24,056)

 

 

 —

 

 

(405,443)

Total property and equipment, net

 

 

242,255 

 

 

17,076 

 

 

 —

 

 

259,331 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other long-term assets:

 

 

 

 

 

 

 

 

 

 

 

 

Goodwill

 

 

283,141 

 

 

52,436 

 

 

 —

 

 

335,577 

Investment in subsidiary

 

 

53,963 

 

 

 —

 

 

(53,963)

 

 

 —

Other intangibles, net

 

 

201,596 

 

 

19,035 

 

 

 —

 

 

220,631 

Other, primarily deferred financing costs, net

 

 

14,409 

 

 

240 

 

 

 —

 

 

14,649 

Total assets

 

$

896,515 

 

$

101,362 

 

$

(82,262)

 

$

915,615 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and Equity

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Current portion of long-term debt

 

$

5,248 

 

$

1,239 

 

$

 —

 

$

6,487 

Book overdrafts

 

 

7,949 

 

 

1,520 

 

 

 —

 

 

9,469 

Due to affiliates

 

 

 —

 

 

28,299 

 

 

(28,299)

 

 

Accounts payable

 

 

28,935 

 

 

3,567 

 

 

 —

 

 

32,502 

Accrued compensation

 

 

9,333 

 

 

2,381 

 

 

 —

 

 

11,714 

Accrued interest

 

 

18,884 

 

 

 —

 

 

 —

 

 

18,884 

Dividend payable

 

 

73 

 

 

 —

 

 

 —

 

 

73 

Other accrued expenses

 

 

10,950 

 

 

81 

 

 

 —

 

 

11,031 

Total current liabilities

 

 

81,372 

 

 

37,087 

 

 

(28,299)

 

 

90,160 

 

 

 

 

 

 

 

 

 

 

 

 

 

Long-term debt, less current portion

 

 

702,381 

 

 

1,903 

 

 

 —

 

 

704,284 

Pension and other long-term liabilities

 

 

7,425 

 

 

 —

 

 

 —

 

 

7,425 

Payable to Parent

 

 

22,669 

 

 

 —

 

 

 —

 

 

22,669 

Deferred income taxes, net

 

 

59,948 

 

 

8,109 

 

 

 —

 

 

68,057 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Additional paid-in capital

 

 

214,505 

 

 

60,019 

 

 

(60,019)

 

 

214,505 

Accumulated deficit

 

 

(181,845)

 

 

(6,056)

 

 

 —

 

 

(187,901)

Accumulated loss in subsidiary

 

 

(6,056)

 

 

 —

 

 

6,056 

 

 

 —

Accumulated other comprehensive loss

 

 

(3,884)

 

 

 —

 

 

 —

 

 

(3,884)

Total Universal Hospital Services, Inc. equity

 

 

22,720 

 

 

53,963 

 

 

(53,963)

 

 

22,720 

Noncontrolling interest

 

 

 —

 

 

300 

 

 

 —

 

 

300 

Total equity

 

 

22,720 

 

 

54,263 

 

 

(53,963)

 

 

23,020 

Total liabilities and equity

 

$

896,515 

 

$

101,362 

 

$

(82,262)

 

$

915,615 

 

18


 

Table of Contents

Universal Hospital Services, Inc.

Consolidating Statements of Operations

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 2014

 

    

Parent

    

Subsidiary

    

    

    

    

 

 

 

Issuer

 

Guarantor

 

Consolidating

 

 

 

 

 

UHS

 

Surgical Services

 

Adjustments

 

Consolidated

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Medical equipment solutions

 

$

67,861 

 

$

 —

 

$

 —

 

$

67,861 

Clinical engineering solutions

 

 

23,717 

 

 

 —

 

 

 —

 

 

23,717 

Surgical services

 

 

 —

 

 

14,887 

 

 

 —

 

 

14,887 

Total revenues

 

 

91,578 

 

 

14,887 

 

 

 —

 

 

106,465 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Cost of medical equipment solutions

 

$

32,204 

 

 

 —

 

 

 —

 

 

32,204 

Cost of clinical engineering solutions

 

 

18,670 

 

 

 —

 

 

 —

 

 

18,670 

Cost of surgical services

 

 

 —

 

 

7,982 

 

 

 —

 

 

7,982 

Medical equipment depreciation

 

 

16,340 

 

 

1,426 

 

 

 —

 

 

17,766 

Total costs of revenues

 

 

67,214 

 

 

9,408 

 

 

 —

 

 

76,622 

Gross margin

 

 

24,364 

 

 

5,479 

 

 

 —

 

 

29,843 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

21,467 

 

 

5,072 

 

 

 —

 

 

26,539 

Operating income

 

 

2,897 

 

 

407 

 

 

 —

 

 

3,304 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity in loss of subsidiary

 

 

111 

 

 

 —

 

 

(111)

 

 

 —

Interest expense

 

 

12,726 

 

 

538 

 

 

 —

 

 

13,264 

Loss before income taxes and noncontrolling interest

 

 

(9,940)

 

 

(131)

 

 

111 

 

 

(9,960)

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision (benefit) for income taxes

 

 

245 

 

 

(20)

 

 

 —

 

 

225 

Consolidated net loss

 

 

(10,185)

 

 

(111)

 

 

111 

 

 

(10,185)

Net income attributable to noncontrolling interest

 

 

 —

 

 

103 

 

 

 —

 

 

103 

Net loss attributable to Universal Hospital Services, Inc.

 

$

(10,185)

 

$

(214)

 

$

111 

 

$

(10,288)

 

19


 

Table of Contents

Universal Hospital Services, Inc.

Consolidating Statements of Operations

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 2013

 

    

Parent

    

Subsidiary

    

    

    

    

 

 

 

Issuer

 

Guarantor

 

Consolidating

 

 

 

 

 

UHS

 

Surgical Services

 

Adjustments

 

Consolidated

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Medical equipment solutions

 

$

68,355 

 

$

 —

 

$

 —

 

$

68,355 

Clinical engineering solutions

 

 

21,839 

 

 

 —

 

 

 —

 

 

21,839 

Surgical services

 

 

 —

 

 

14,084 

 

 

 —

 

 

14,084 

Total revenues

 

 

90,194 

 

 

14,084 

 

 

 —

 

 

104,278 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Cost of medical equipment solutions

 

$

31,107 

 

 

 —

 

 

 —

 

 

31,107 

Cost of clinical engineering solutions

 

 

16,310 

 

 

 —

 

 

 —

 

 

16,310 

Cost of surgical services

 

 

 —

 

 

7,921 

 

 

 —

 

 

7,921 

Medical equipment depreciation

 

 

17,189 

 

 

1,125 

 

 

 —

 

 

18,314 

Total costs of revenues

 

 

64,606 

 

 

9,046 

 

 

 —

 

 

73,652 

Gross margin

 

 

25,588 

 

 

5,038 

 

 

 —

 

 

30,626 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

22,393 

 

 

4,677 

 

 

 —

 

 

27,070 

Operating income

 

 

3,195 

 

 

361 

 

 

 —

 

 

3,556 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity in income of subsidiary

 

 

(1,104)

 

 

 —

 

 

1,104 

 

 

 —

Interest expense

 

 

13,314 

 

 

520 

 

 

 —

 

 

13,834 

Loss before income taxes and noncontrolling interest

 

 

(9,015)

 

 

(159)

 

 

(1,104)

 

 

(10,278)

 

 

 

 

 

 

 

 

 

 

 

 

 

Benefit for income taxes

 

 

(50)

 

 

(1,263)

 

 

 —

 

 

(1,313)

Consolidated net (loss) income

 

 

(8,965)

 

 

1,104 

 

 

(1,104)

 

 

(8,965)

Net income attributable to noncontrolling interest

 

 

 —

 

 

216 

 

 

 —

 

 

216 

Net (loss) income attributable to Universal Hospital Services, Inc.

 

$

(8,965)

 

$

888 

 

$

(1,104)

 

$

(9,181)

 

20


 

Table of Contents

Universal Hospital Services, Inc.

Consolidating Statements of Operations

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30, 2014

 

    

Parent

    

Subsidiary

    

    

    

    

 

 

 

Issuer

 

Guarantor

 

Consolidating

 

 

 

 

 

UHS

 

Surgical Services

 

Adjustments

 

Consolidated

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Medical equipment solutions

 

$

216,771 

 

$

 —

 

$

 —

 

$

216,771 

Clinical engineering solutions

 

 

68,505 

 

 

 —

 

 

 —

 

 

68,505 

Surgical services

 

 

 —

 

 

43,890 

 

 

 —

 

 

43,890 

Total revenues

 

 

285,276 

 

 

43,890 

 

 

 —

 

 

329,166 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Cost of medical equipment solutions

 

$

97,919 

 

 

 —

 

 

 —

 

 

97,919 

Cost of clinical engineering solutions

 

 

54,454 

 

 

 —

 

 

 —

 

 

54,454 

Cost of surgical services

 

 

 —

 

 

24,418 

 

 

 —

 

 

24,418 

Medical equipment depreciation

 

 

51,843 

 

 

4,153 

 

 

 —

 

 

55,996 

Total costs of revenues

 

 

204,216 

 

 

28,571 

 

 

 —

 

 

232,787 

Gross margin

 

 

81,060 

 

 

15,319 

 

 

 —

 

 

96,379 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

70,732 

 

 

14,684 

 

 

 —

 

 

85,416 

Restructuring, acquisition and integration expenses

 

 

1,820 

 

 

 —

 

 

 —

 

 

1,820 

Intangible asset impairment charge

 

 

34,900 

 

 

 —

 

 

 —

 

 

34,900 

Operating (loss) income

 

 

(26,392)

 

 

635 

 

 

 —

 

 

(25,757)

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity in loss of subsidiary

 

 

312 

 

 

 —

 

 

(312)

 

 

 —

Interest expense

 

 

38,322 

 

 

1,600 

 

 

 —

 

 

39,922 

Loss before income taxes and noncontrolling interest

 

 

(65,026)

 

 

(965)

 

 

312 

 

 

(65,679)

 

 

 

 

 

 

 

 

 

 

 

 

 

Benefit for income taxes

 

 

(12,579)

 

 

(653)

 

 

 —

 

 

(13,232)

Consolidated net loss

 

 

(52,447)

 

 

(312)

 

 

312 

 

 

(52,447)

Net income attributable to noncontrolling interest

 

 

 —

 

 

364 

 

 

 —

 

 

364 

Net loss attributable to Universal Hospital Services, Inc.

 

$

(52,447)

 

$

(676)

 

$

312 

 

$

(52,811)

 

21


 

Table of Contents

Universal Hospital Services, Inc.

Consolidating Statements of Operations

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30, 2013

 

    

Parent

    

Subsidiary

    

    

    

    

 

 

 

Issuer

 

Guarantor

 

Consolidating

 

 

 

 

 

UHS

 

Surgical Services

 

Adjustments

 

Consolidated

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Medical equipment solutions

 

$

215,141 

 

$

 —

 

$

 —

 

$

215,141 

Clinical engineering solutions

 

 

65,000 

 

 

 —

 

 

 —

 

 

65,000 

Surgical services

 

 

 —

 

 

41,486 

 

 

 —

 

 

41,486 

Total revenues

 

 

280,141 

 

 

41,486 

 

 

 —

 

 

321,627 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Cost of medical equipment solutions

 

$

94,918 

 

 

 —

 

 

 —

 

 

94,918 

Cost of clinical engineering solutions

 

 

50,120 

 

 

 —

 

 

 —

 

 

50,120 

Cost of surgical services

 

 

 —

 

 

23,175 

 

 

 —

 

 

23,175 

Medical equipment depreciation

 

 

50,620 

 

 

4,050 

 

 

 —

 

 

54,670 

Total costs of revenues

 

 

195,658 

 

 

27,225 

 

 

 —

 

 

222,883 

Gross margin

 

 

84,483 

 

 

14,261 

 

 

 —

 

 

98,744 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

73,076 

 

 

14,170 

 

 

 —

 

 

87,246 

Restructuring, acquisition and integration expenses

 

 

(129)

 

 

365 

 

 

 —

 

 

236 

Operating income (loss)

 

 

11,536 

 

 

(274)

 

 

 —

 

 

11,262 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity in loss of subsidiary

 

 

44 

 

 

 —

 

 

(44)

 

 

 —

Loss on extinguishment of debt

 

 

1,853 

 

 

 —

 

 

 —

 

 

1,853 

Interest expense

 

 

40,064 

 

 

1,593 

 

 

 —

 

 

41,657 

Loss before income taxes and noncontrolling interest

 

 

(30,425)

 

 

(1,867)

 

 

44 

 

 

(32,248)

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision (benefit) for income taxes

 

 

1,425 

 

 

(1,823)

 

 

 —

 

 

(398)

Consolidated net loss

 

 

(31,850)

 

 

(44)

 

 

44 

 

 

(31,850)

Net income attributable to noncontrolling interest

 

 

 —

 

 

532 

 

 

 —

 

 

532 

Net loss attributable to Universal Hospital Services, Inc.

 

$

(31,850)

 

$

(576)

 

$

44 

 

$

(32,382)

 

 

22


 

Table of Contents

Universal Hospital Services, Inc.

Consolidating Statements of Comprehensive Income (Loss)

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 2014

 

Nine Months Ended September 30, 2014

 

    

Parent

    

Subsidiary

    

    

    

    

 

 

Parent

    

Subsidiary

    

    

    

    

 

 

 

Issuer

 

Guarantor

 

Consolidating

 

 

 

 

Issuer

 

Guarantor

 

Consolidating

 

 

 

 

 

UHS

 

Surgical Services

 

Adjustments

 

Consolidated

 

UHS

 

Surgical Services

 

Adjustments

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated net loss

 

$

(10,185)

 

$

(111)

 

$

111 

 

$

(10,185)

 

$

(52,447)

 

$

(312)

 

$

312 

 

$

(52,447)

Total other comprehensive income

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Comprehensive loss

 

 

(10,185)

 

 

(111)

 

 

111 

 

 

(10,185)

 

 

(52,447)

 

 

(312)

 

 

312 

 

 

(52,447)

Comprehensive income attributable to noncontrolling interest

 

 

 —

 

 

103 

 

 

 —

 

 

103 

 

 

 —

 

 

364 

 

 

 —

 

 

364 

Comprehensive loss attributable to Universal Hospital Services, Inc.

 

$

(10,185)

 

$

(214)

 

$

111 

 

$

(10,288)

 

$

(52,447)

 

$

(676)

 

$

312 

 

$

(52,811)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 2013

 

Nine Months Ended September 30, 2013

 

    

Parent

    

Subsidiary

    

    

    

    

 

 

Parent

    

Subsidiary

    

    

    

    

 

 

 

Issuer

 

Guarantor

 

Consolidating

 

 

 

 

Issuer

 

Guarantor

 

Consolidating

 

 

 

 

 

UHS

 

Surgical Services

 

Adjustments

 

Consolidated

 

UHS

 

Surgical Services

 

Adjustments

 

Consolidated

Consolidated net (loss) income

 

$

(8,965)

 

$

1,104 

 

$

(1,104)

 

$

(8,965)

 

$

(31,850)

 

$

(44)

 

$

44 

 

$

(31,850)

Total other comprehensive income

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Comprehensive (loss) income

 

 

(8,965)

 

 

1,104 

 

 

(1,104)

 

 

(8,965)

 

 

(31,850)

 

 

(44)

 

 

44 

 

 

(31,850)

Comprehensive income attributable to noncontrolling interest

 

 

 —

 

 

216 

 

 

 —

 

 

216 

 

 

 —

 

 

532 

 

 

 —

 

 

532 

Comprehensive (loss) income attributable to Universal Hospital Services, Inc.

 

$

(8,965)

 

$

888 

 

$

(1,104)

 

$

(9,181)

 

$

(31,850)

 

$

(576)

 

$

44 

 

$

(32,382)

 

23


 

Table of Contents

Universal Hospital Services, Inc.

Consolidating Statements of Cash Flows

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30, 2014

 

    

Parent

    

Subsidiary

    

    

    

    

 

 

 

Issuer

 

Guarantor

 

Consolidating

 

 

 

 

 

UHS

 

Surgical Services

 

Adjustments

 

Consolidated

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated net loss

 

$

(52,447)

 

$

(312)

 

$

312 

 

$

(52,447)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

59,139 

 

 

4,981 

 

 

 —

 

 

64,120 

Assets impairment charges

 

 

2,025 

 

 

 —

 

 

 —

 

 

2,025 

Intangible assets impairment charge

 

 

34,900 

 

 

 —

 

 

 —

 

 

34,900 

Amortization of intangibles, deferred financing costs and bond premium

 

 

7,877 

 

 

2,482 

 

 

 —

 

 

10,359 

Equity in loss of subsidiary

 

 

312 

 

 

 —

 

 

(312)

 

 

 —

Provision for doubtful accounts

 

 

661 

 

 

(3)

 

 

 —

 

 

658 

Provision for inventory obsolescence

 

 

(16)

 

 

(11)

 

 

 —

 

 

(27)

Non-cash share-based compensation expense - net

 

 

626 

 

 

175 

 

 

 —

 

 

801 

Gain on sales and disposals of equipment

 

 

(1,776)

 

 

(15)

 

 

 —

 

 

(1,791)

Deferred income taxes

 

 

(11,345)

 

 

(2,200)

 

 

 —

 

 

(13,545)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable

 

 

1,788 

 

 

(121)

 

 

 —

 

 

1,667 

Due from (to) affiliates

 

 

(2,529)

 

 

2,529 

 

 

 —

 

 

 —

Inventories

 

 

593 

 

 

(846)

 

 

 —

 

 

(253)

Other operating assets

 

 

(2,090)

 

 

(47)

 

 

 —

 

 

(2,137)

Accounts payable

 

 

498 

 

 

(277)

 

 

 —

 

 

221 

Other operating liabilities

 

 

(9,757)

 

 

483 

 

 

 —

 

 

(9,274)

Net cash provided by operating activities

 

 

28,459 

 

 

6,818 

 

 

 —

 

 

35,277 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Medical equipment purchases

 

 

(40,270)

 

 

(4,293)

 

 

 —

 

 

(44,563)

Property and office equipment purchases

 

 

(3,420)

 

 

(190)

 

 

 —

 

 

(3,610)

Proceeds from disposition of property and equipment

 

 

6,919 

 

 

77 

 

 

 —

 

 

6,996 

Purchases of noncontrolling interests

 

 

 —

 

 

(46)

 

 

 —

 

 

(46)

Net cash used in investing activities

 

 

(36,771)

 

 

(4,452)

 

 

 —

 

 

(41,223)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds under senior secured credit facility

 

 

123,400 

 

 

 —

 

 

 —

 

 

123,400 

Payments under senior secured credit facility

 

 

(107,200)

 

 

 —

 

 

 —

 

 

(107,200)

Payments of principal under capital lease obligations

 

 

(4,198)

 

 

(1,001)

 

 

 —

 

 

(5,199)

Distributions to noncontrolling interests

 

 

 —

 

 

(436)

 

 

 —

 

 

(436)

Dividend and equity distribution payments

 

 

(73)

 

 

 —

 

 

 —

 

 

(73)

Change in book overdrafts

 

 

(3,617)

 

 

(929)

 

 

 —

 

 

(4,546)

Net cash provided by (used in) financing activities

 

 

8,312 

 

 

(2,366)

 

 

 —

 

 

5,946 

Net change in cash and cash equivalents

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Cash and cash equivalents at the beginning of period

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Cash and cash equivalents at the end of period

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

24


 

Table of Contents

Universal Hospital Services, Inc.

Consolidating Statements of Cash Flows

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30, 2013

 

    

Parent

    

Subsidiary

    

    

    

    

 

 

 

Issuer

 

Guarantor

 

Consolidating

 

 

 

 

 

UHS

 

Surgical Services

 

Adjustments

 

Consolidated

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated net loss

 

$

(31,850)

 

$

(44)

 

$

44 

 

$

(31,850)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

58,531 

 

 

4,626 

 

 

 —

 

 

63,157 

Amortization of intangibles, deferred financing costs and bond premium

 

 

9,499 

 

 

2,518 

 

 

 —

 

 

12,017 

Non-cash write off of deferred financing cost

 

 

1,853 

 

 

 —

 

 

 —

 

 

1,853 

Equity in loss of subsidiary

 

 

44 

 

 

 —

 

 

(44)

 

 

 —

Provision for doubtful accounts

 

 

1,377 

 

 

(161)

 

 

 —

 

 

1,216 

Provision for inventory obsolescence

 

 

64 

 

 

(42)

 

 

 —

 

 

22 

Non-cash share-based compensation expense - net

 

 

452 

 

 

157 

 

 

 —

 

 

609 

Gain on sales and disposals of equipment

 

 

(1,055)

 

 

(15)

 

 

 —

 

 

(1,070)

Deferred income taxes

 

 

1,595 

 

 

(862)

 

 

 —

 

 

733 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(299)

 

 

374 

 

 

 —

 

 

75 

Due from (to) affiliates

 

 

(2,490)

 

 

2,490 

 

 

 —

 

 

 —

Inventories

 

 

100 

 

 

(1,089)

 

 

 —

 

 

(989)

Other operating assets

 

 

(283)

 

 

84 

 

 

 —

 

 

(199)

Accounts payable

 

 

(419)

 

 

(336)

 

 

 —

 

 

(755)

Other operating liabilities

 

 

(8,039)

 

 

(1,302)

 

 

 —

 

 

(9,341)

Net cash provided by operating activities

 

 

29,080 

 

 

6,398 

 

 

 —

 

 

35,478 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Medical equipment purchases

 

 

(36,895)

 

 

(2,904)

 

 

 —

 

 

(39,799)

Property and office equipment purchases

 

 

(6,008)

 

 

(319)

 

 

 —

 

 

(6,327)

Proceeds from disposition of property and equipment

 

 

2,612 

 

 

20 

 

 

 —

 

 

2,632 

Holdback payment related to acquisition

 

 

 —

 

 

(1,655)

 

 

 —

 

 

(1,655)

Net cash used in investing activities

 

 

(40,291)

 

 

(4,858)

 

 

 —

 

 

(45,149)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds under senior secured credit facility

 

 

82,900 

 

 

 —

 

 

 —

 

 

82,900 

Payments under senior secured credit facility

 

 

(66,700)

 

 

 —

 

 

 —

 

 

(66,700)

Payments of principal under capital lease obligations

 

 

(4,659)

 

 

(1,020)

 

 

 —

 

 

(5,679)

Payments of floating rate notes

 

 

(230,000)

 

 

 —

 

 

 —

 

 

(230,000)

Proceeds from issuance of bonds

 

 

234,025 

 

 

 —

 

 

 —

 

 

234,025 

Accrued interest received from bondholders

 

 

8,620 

 

 

 —

 

 

 —

 

 

8,620 

Accrued interest paid to bondholders

 

 

(8,620)

 

 

 —

 

 

 —

 

 

(8,620)

Distributions to noncontrolling interests

 

 

 —

 

 

(528)

 

 

 —

 

 

(528)

Payment of deferred financing costs

 

 

(4,116)

 

 

 —

 

 

 —

 

 

(4,116)

Change in book overdrafts

 

 

(239)

 

 

 

 

 —

 

 

(231)

Net cash provided by (used in) financing activities

 

 

11,211 

 

 

(1,540)

 

 

 —

 

 

9,671 

Net change in cash and cash equivalents

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Cash and cash equivalents at the beginning of period

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Cash and cash equivalents at the end of period

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

 

 

 

25


 

Table of Contents

15. Restructuring

 

We incurred restructuring expense of $1.8 and $0.2 million during the nine months ended September 30, 2014 and 2013, respectively, the majority of which related to severances and other related expenses. We incurred no restructuring expense during the three months ended September 30, 2014 and 2013. In addition, we recorded $0.4 million during the nine months ended September 30, 2013 for cancellation of outstanding stock options for certain terminated employees, which was recorded as reduction to Payable to Parent in the Consolidated Balance Sheets. The restructuring expense impact was recorded under the Corporate and Unallocated segment. As of December 31, 2013, we had $0.3 million of restructuring liability. For the nine months ended September 30, 2014, $ 1.5 million in restructuring charges was paid. An additional provision of $1.8 million was recorded in the first three quarters of 2014 for new severance arrangements and the remaining liability of $ 0.6 million as of September 30, 2014 is expected to be paid out by the end of the third quarter of 2015 and is included in the Other accrued expenses in the Consolidated Balance Sheets. As of December 31, 2012, we had $4.8 million of restructuring liability. For the nine months ended September 30, 2013, we incurred restructuring expense of $0.2 million and $4.2 million in restructuring charges was paid and the remaining $0.8 was a liability as of September 30, 2013.

 

16. Concentration

 

One customer accounted for approximately 14% of total revenue for the nin e months ended September 30 , 2014 and 2013.

 

17. Subsequent Events

 

On October 24, 2014, Timothy W. Kuck resigned from his position as Executive Vice President, Strategy and Business Development of the Company effective November 1, 2014.  In connection with his resignation, Mr. Kuck has entered into a mutual termination agreemen t (“MTA”) with the Company effective November 1, 2014.  This MTA includes customary non-competition and release provisions in exchange for separation payments totaling approximately $346,245 along with other benefits.  In addition, Mr. Kuck will receive a payment totaling approximately $232,291, which represents a pro-rated portion of the incentive compensation for the fiscal year ending December 31, 2014 for which he was eligible under the terms of the Company’s Executive Incentive Program (“EIP”), to be paid in accordance with the Company’s normal year-end procedure. 

 

Effective November 4, 2014, the Compensation Committee of our Board of Directors recommended, and the board of directors (the “Parent Board”) of Parent, approved, an amendment (the “Amendment”) to the 2007 Stock Option Plan to remove the 2007 Stock Option Plan’s mandatory ten year limit on the duration of stock options. In addition, the Compensation Committee recommended, and the Parent Board approv ed, unilateral amendments to certain outstanding stock option agreements. These amendments extend the expiration date of such options to November   4, 202 4 and reset the option exercise price at $0.71 per share, which was the fair market value of Parent’s common stock on the amendment date as determined by a third party valuation obtained by the Parent Board. The original options were granted from June 18, 2007 to May 21, 2013 with exercise prices ranging from $1.00 to $1.83. The Amendment to the 2007 Stock Option Plan and the amendments to the individual options do not change the number of options granted, the vesting commencement date, the vesting schedules or any continued service requirements. The amendment will result in additional stock compensation expense estimated at $2 to $ 3 million, of which approximately $1 million will be recognized in 2014.

 

 

26


 

Table of Contents

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following should be read in conjunction with the accompanying consolidated financial statements and notes.

 

BUSINESS OVERVIEW

 

Our Company

 

Universal Hospital Services, Inc. (“we”, “our”, “us”, the “Company”, or “UHS”) is a leading nationwide provider of health care technology management and service solutions to the United States health care industry. We provide our customers comprehensive health care technology management, service and clinical solutions that we believe help reduce capital and operating expenses, increase medical equipment and staff productivity , and support improved patient safety and outcomes.

 

We commenced operations in 1939, originally incorporated in Minnesota in 1954 and reincorporated in Delaware in 2001. All of our outstanding capital stock is owned by UHS Holdco, Inc. (“Parent”), which acquired the Company in a recapitalization in May 2007.  Parent is owned by affiliates of Irving Place Capital Merchant Manager III, L.P. (“IPC”) and certain members of our management.

 

UHS delivers health care solutions through three segments: Medical Equipment Solutions (“MES”), Clinical Engineering Solutions (“CES”) and S urgical Services (“SS”). As of September  30, 2014, we owned or managed over 700,000 units of medical equipment consisting of approximately 450,000 owned or managed units in our MES segment, over 250,000 units of customer-owned equipment we managed in our CES segment and over 4,000 units of owned or managed mobile surgical equipment in our SS segment. Our diverse customer base includes more than 8,000 national, regional and local acute care hospitals and alternate site providers (such as long-term acute care hospitals, skilled nursing facilities, surgery centers, specialty hospitals, nursing homes and home care providers). We also have relationships with more than 200 medical device manufacturers, many of the nation’s largest group purchasing organizations (“GPOs”) and many health system integrated delivery networks (“IDNs”).  All of our solutions leverage our nationwide network of 84 district service centers, five CES Centers of Excellence and an additional seven stand-alone SS service centers, together with our more than 75 years of experience managing and servicing all aspects of medical equipment.  Our fees are paid directly by our customers rather than by direct reimbursement from third-party payors, such as private insurers, Medicare or Medicaid.

 

We report our financial results in three segments. Our reporting segments consist of MES, CES and SS . We evaluate the performance of our reportable segments based on gross margin. The accounting policies of the individual reportable segments are the same as those of the entire company.

 

In June 2014, Smith & Nephew announced that it had ceased commercial distribution of the RENASYS Negative Pressure Wound Therapy (“NPWT”) product line in the United States following a request from the FDA to obtain additional regulatory clearances through the premarket notification 510(k) process with respect to certain design modifications made to the RENASYS product line.  Subsequently, the FDA authorized limited distribution by Smith & Nephew of these products under a Certificate of Medical Necessity (“CMN”) program.  The Company is unable to predict when or whether Smith & Nephew will resume full commercial distribution of the RENASYS product line but it has been informed by Smith & Nephew that the 510(k) clearances for these products will take at least three months and probably longer, and that Smith & Nephew is requesting that customers using a CMN transition to alternative NPWT providers by no later than August 31, 2014.  The RENASYS product line generated approximately $24 million in annual revenue for the prior twelve month period ended June 30, 2014 from device rental ($14 million) and disposable sales ($10 million) which was included in our MES segment.  The net book value of the equipment approximates $ 4 million as of the end of September  2014.  The Company is working with our customers to provide alternative solutions. In late July, the Company signed an agreement with a NPWT manufacturer to provide an alternative solution to our customers, and we have secured over $ 3 million in annualized rental revenue contracts with our customers.  However, many of our customers have met, or may in the future seek to meet, their NPWT needs directly with other manufacturers or service providers.  The Company’s future financial results will be negatively impacted by the interruption of commercial distribution of the RENASYS product line and we anticipate losing the majority of the disposable portion of our revenue based on the new agreement with an alternative NPWT manufacturer. The gross margin on the disposable portion of the business is significantly lower than the overall MES segment gross margin . The potential impact will be highly

27


 

Table of Contents

dependent upon the outcome of the factors mentioned above.  The Company is currently assessing the financial impact to our business and, while highly sensitive to the outcome of the above factors, the Company estimates the net loss in revenue at $ 7 to $ 9 million for 2014.

 

In July 2014, the Company was notified that a national group purchasing organization (“GPO”) awarded a sole source agreement to a competitor of the Company, for all peak need rental equipment, therapy surfaces (wound and pulmonary) and bariatric equipment. This GPO currently has agreements for the purchase or rental of this equipment with multiple vendors, including from the Company under agreements that are expiring December 31 , 2014 .  Under these agreements, the Company supplies equipment to its GPO member customers.  T he Com pany generated approximately $26 million of business (over the prior twelve month period ended September 30 ) in the portions of the business covered under this new agreement which was included in our MES segment.  In addition, t he Company also maintains certain 360 solutions with customers that are members of this GPO.   The Company is working with the national GPO and its members to develop an orderly transition and anticipates that this transition will occur over the next several months. The Company is currently assessing the financial impact to its business and the impact will be dependent upon several factors including the GPO members’ willingness to contract with the Company as a non-contracted vendor and the ability of the new service provider to service all of these GPO members.  The Company’s future results will be negatively impacted by the loss of this agreement and, while highly sensitive to the factors mentioned above, the loss in revenue is estimated at $ 2 to $ 4 million for the balance of 2014 and estimated at $15 to $20 million on an annual basis . The Company anticipates either selling or redeploying approximately $6 to $8 million in excess equipment currently supporting the existing business , which will reduce the on-going maintenance capital expenditures .

 

Medical Equipment Solutions

 

Our MES segment accounted for $67.9 and $ 68.4 million, or approximately 63.7% and   65.6 % of our revenues, for the three months ended September  30, 2014 and 2013 , respectively and $216.8 and   $ 215.1 million, or approximately 6 5 .9% and 66.9 % of our revenues, for the nine months ended September  30, 2014 and 2013, respectively. As of September  30, 2014, the MES segment owned or managed approximately 450,000 units of medical equipment ranging across hundreds of clinical categories, manufacturers and models.  These solutions are provided primarily to hospitals and other acute care providers for use through their facilities, including the emergency room, operating room, critical care, intensive care, rehabilitation and general patient care areas.

 

Our MES segment started more than 75 years ago as our leading medical equipment peak needs usage business and has transformed into providing comprehensive outsourced and on-site solutions that manage all aspects of medical equipment in a health care facility. We currently provide MES solutions to more than 8,000 acute care hospitals and alternate site providers in the United States, including some of the nation’s premier health care institutions. Historically, we have purchased and owned directly the equipment used in our MES programs. We expect much of our future growth in this segment to be driven by our customers outsourcing more of their medical equipment needs and taking full advantage of our diversified product offering, clinical education and support, customized agreements and 360 On-site Managed Solutions.

 

We have four primary solutions in our MES segment:

 

·

Supplemental and Peak Needs Usage Solutions;

·

Customized Equipment Agreements Solutions;

·

360 On-site Managed Solutions; and

·

Specialty Medical Equipment Sales, Distribution and Disposal Solutions.

 

Clinical Engineering Solutions

 

Our CES segment accounted for $2 3.7 and $21.8 million, or approximately 22.3% and 20.9 % of our revenues, for the three months ended September  30, 2014 and 2013, respectively and $ 68.5 and   $ 65.0 million, or approximately 20. 8 % and 20.2 % of our revenues, for the nine months ended September  30, 2014 and 2013, respectively. We offer a broad range of inspection, preventive maintenance, repair, logistic and consulting services through our team of over 370 technicians and professionals located throughout the United States in our nationwide network of service centers.  We managed over 250,000 units of customer owned equipment as of September  30, 2014.  In addition, as of September  30, 2014, we serviced approximately 450,000 units that we own or directly manage.

28


 

Table of Contents

 

Our CES segment leverages our over 75 years of experience and our extensive equipment database in repairing and maintaining a broad range of health care technologies. Historically, we have been our own largest customer for CES services in order to repair and maintain approximately 450,000 units that we own or directly manage. However, we believe our CES segment has significant future growth potential by offering non-capital based comprehensive solutions as a stand-alone or complementary alternative for customers that own medical equipment but lack the infrastructure, expertise, or scale to perform routine maintenance, repair, record keeping, and lifecycle analysis and planning functions.  We also believe hospital and other facility-based clients will face increasing challenges in managing sophisticated medical equipment that requires connectivity and interoperability with information technology systems, compliance with the 10 th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10), regulatory requirements, integration with EMR, maintenance and management of software databases and management of other medical equipment patient information and safety features.

 

We have three primary solutions in our CES segment:

 

·

Supplemental Maintenance and Repair Solutions;

·

360 On-site Managed Solutions; and

·

Health Care Technology Advisory Solutions.

 

Surgical Services

 

Our SS segment accounted for $1 4.9 and $14.1 million, or approximately 1 4.0 % and   13.5% of our revenues, for the three months ended September  30, 2014 and 2013, respectively and $ 43. 9 and   $ 41.5 million, or approximately 13. 3 % and 12. 9 % of our revenues, for the nine months ended September  30, 2014 and 2013, respectively. As of September  30, 2014, we owned or managed over 4,000 units of mobile surgical equipment in our SS segment, primarily used in the practice of general surgery, orthopedic surgery, otolaryngology, urology, obstetrics, gynecology, podiatry, dermatology and plastic/cosmetics.

 

SS provides high end, state-of-the-art surgical equipment and associated products along with trained and certified Surgical Equipment Technologists (“technologists”) to assist in the procedural operation of the equipment. We provide these services to over 1,000 acute care hospitals and surgery centers through our nationwide network of 84 district service centers and an additional seven stand-alone SS service centers. Our technologists work in the operating room (“O.R.”) and support physicians and O.R. personnel. The services are offered on a per-procedure basis. Our technologists deliver, set up, and create a safe environment for hospital and clinical personnel operating the equipment and provide all necessary disposable materials needed. Our technologists work closely with our customers to confirm that all certifications and credentials meet requirements to provide on-site services. Our technologists also assist customers in the operation of facility-owned assets and supplement the training and staffing of their personnel.  As of September  30, 2014, SS provided solutions in 4 2 states.

 

We have two primary solutions in our SS segment:

 

·

On-Demand and Scheduled Usage Solutions; and

·

360 On-site Managed Solutions.

 

RESULTS OF OPERATIONS

 

The following discussion addresses:

 

·

our financial condition as of September 30, 2014 and

·

the results of operations for the three-month and nine-month periods ended September 30, 2014 and 2013.

 

This discussion should be read in conjunction with the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q and the Management’s Discussion and Analysis of Financial Condition and Results of Operations section included in our 2013 Annual Report on Form 10-K, filed with the Securities and Exchange Commission.

 

29


 

Table of Contents

The following table provides information on the percentages of certain items of selected financial data compared to total revenues for the three-month and nine-month periods ended September 30, 2014 and 2013.  The table below also indicates the percentage increase or decrease over the prior comparable period.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Percent to Total Revenues

 

Percent

 

Percent to Total Revenues

 

Percent

 

 

 

Three Months Ended September 30,

 

Increase

 

Nine Months Ended September 30,

 

Increase

 

 

    

2014

    

2013

    

(Decrease)

    

2014

    

2013

    

(Decrease)

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

Medical equipment solutions

 

63.7 

%  

65.6 

%  

(0.7)

%  

65.9 

%  

66.9 

%  

0.8 

%  

Clinical engineering solutions

 

22.3 

 

20.9 

 

8.6 

 

20.8 

 

20.2 

 

5.4 

 

Surgical services

 

14.0 

 

13.5 

 

5.7 

 

13.3 

 

12.9 

 

5.8 

 

Total revenues

 

100.0 

%  

100.0 

%  

2.1 

 

100.0 

%  

100.0 

%  

2.3 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of medical equipment solutions

 

30.2 

 

29.8 

 

3.5 

 

29.7 

 

29.5 

 

3.2 

 

Cost of clinical engineering solutions

 

17.5 

 

15.6 

 

14.5 

 

16.5 

 

15.6 

 

8.6 

 

Cost of surgical services

 

7.5 

 

7.6 

 

0.8 

 

7.4 

 

7.2 

 

5.4 

 

Medical equipment depreciation

 

16.7 

 

17.6 

 

(3.0)

 

17.0 

 

17.0 

 

2.4 

 

Total costs of revenues

 

71.9 

 

70.6 

 

4.0 

 

70.6 

 

69.3 

 

4.4 

 

Gross margin

 

28.1 

 

29.4 

 

(2.6)

 

29.4 

 

30.7 

 

(2.4)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

24.9 

 

26.0 

 

(2.0)

 

25.9 

 

27.1 

 

(2.1)

 

Restructuring, acquisition and integration expenses

 

 —

 

 —

 

*

 

0.6 

 

0.1 

 

*

 

Intangible asset impairment charge

 

 —

 

 

*

 

10.6 

 

 

*

 

Operating income (loss)

 

3.2 

 

3.4 

 

*

 

(7.7)

 

3.5 

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss on extinguishment of debt

 

 

 

*

 

 

0.6 

 

*

 

Interest expense

 

12.5 

 

13.3 

 

(4.1)

 

12.1 

 

13.0 

 

(4.2)

 

Loss before income taxes and noncontrolling interest

 

(9.3)

 

(9.9)

 

*

 

(19.8)

 

(10.1)

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision (benefit) for income taxes

 

0.2 

 

(1.3)

 

*

 

(4.0)

 

(0.1)

 

*

 

Consolidated net loss

 

(9.5)

%

(8.6)

%

*

 

(15.8)

%

(10.0)

%

*

 


*Not meaningful

 

Consolidated Results of Operations for the three months ended September 30, 2014 compared to the three months ended September 30, 2013

 

Total Revenue

 

Total revenue for the three months ended September 30, 2014 was $106.5 million, compared to $104.3 million for the three months ended September 30, 2013, an increase of $2.2 million or 2.1% .  The increase was primarily due to additional revenue in our MES segment related to growth in our 360 On-site Managed Solutions (“360 solutions”) of $3.4 million and growth in our CES segment of $1.9 million related to growth in our 360 solutions. These increases were partially offset by the decline in NPWT device rental and disposable sales due to the interruption of Smith & Nephew commercial distribution of the RENASYS product line.

 

30


 

Table of Contents

Cost of Revenue

 

Total cost of revenue for the three months ended September 30, 2014 was $76.6 million compared to $73.7 million for the three months ended September 30, 2013, an increase of $2.9 million or 4.0% . The increase was primarily in our MES segment due to an increase in 360 solutions cost of $2.6 million and an increase in our CES 360 solutions cost of $1.7 corresponding with the 360 solutions revenue growth of $5.3 million.

 

Gross Margin

 

Total gross margin for the three months ended September 30, 2014 was $29.8 million, or 28.1% of total revenues, compared to $30.6 million, or 29.4% of total revenues, for the three months ended September 30, 2013, a decrease of $0.8 million or 2.6% .  The decrease in gross margin as a percent of revenue for the quarter was primarily impacted by business mix with CES growth and an increase in repair and maintenance and service cost for certain program offerings.

 

Medical Equipment Solutions

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

 

    

2014

    

2013

    

Change

    

% Change

 

Total revenue

 

$

67,861 

 

$

68,355 

 

$

(494)

 

(0.7)

%  

Cost of revenue

 

 

32,204 

 

 

31,107 

 

 

1,097 

 

3.5 

 

Medical equipment depreciation

 

 

16,340 

 

 

17,189 

 

 

(849)

 

(4.9)

 

Gross margin

 

$

19,317 

 

$

20,059 

 

$

(742)

 

(3.7)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross margin %

 

 

28.5 

%  

 

29.3 

%  

 

 

 

 

 

 

Total revenue in the MES segment decreased $0.5 million, or 0.7% , to $67.9  m illion in the third quarter of 2014 as compared to the same period of 2013.  The decrease was primarily due to growth in our 360 solutions from both new programs and expansion of existing programs of $3.4 million, which was offset by a decrease related to the decline in NPWT device rental and disposable sales due to the interruption of Smith & Nephew commercial distribution of the RENASYS product line of approximately $3.0 million . Many of our 360 Solution customers utilize more than one of our equipment management program offerings in areas such as infusion, patient handling and negative pressure wound therapy. As of September 30, 2014, we had 203 such active programs, up from 181 as of December 31, 2013.

 

Total cost of revenue in the segment increased $1.1 million, or 3.5% , to $32.2 million in the third quarter of 2014 as compared to the same period of 2013.  This increase is due to an increase in costs to support growth in our 360 solutions of $2.6 million largely due to an increase in employee related expense of $ 1.3 million and an increase in repair and maintenance and service cost for certain program offerings, partially offset by lower cost of disposables.

 

Medical equipment depreciation decreased $0.8 million, or 4.9% , to $16.3 million in the third quarter of 2014 as compared to the same period of 2013. The decrease in medical equipment depreciation was primarily due to reduced depreciation rate resulting from disposals of certain medical equipment.

 

Gross margin percentage for the MES segment decreased from 29.3% in the third quarter of 2013 to 28.5% in the same period of 2014. Gross margin rate was impacted by an increase in repair and maintenance and service cost for certain program offerings, as well as growth in our 360 solutions, which has a lower margin rate than other medical equipment solutions.

 

Future revenue will be negatively impacted by the loss of revenues resulting from the pending FDA 510(k) clearances on RENASYS NPWT product line and the loss of the agreement related to a national GPO.

31


 

Table of Contents

Clinical Engineering Solutions

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

 

    

2014

    

2013

    

Change

    

% Change

 

Total revenue

 

$

23,717 

 

$

21,839 

 

$

1,878 

 

8.6 

%  

Cost of revenue

 

 

18,670 

 

 

16,310 

 

 

2,360 

 

14.5 

 

Gross margin

 

$

5,047 

 

$

5,529 

 

$

(482)

 

(8.7)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross margin %

 

 

21.3 

%  

 

25.3 

%  

 

 

 

 

 

 

Total revenue in the CES segment increased $1.9 million, or 8.6% , to $23.7 million in the third quarter of 2014 as compared to the same period of 2013. The increase was primarily due to growth in our managed 360 solutions, partially offset with weakness in services supporting key manufacturers. As of September 30, 2014, we had 360 solutions implemented in 142 programs in our CES segment, up from 131 programs as of December 31, 2013 .

 

Total cost of revenue in the segment increased $2.4 million, or 14.5% , to $18.7 million in the third quarter of 2014 as compared to the same period of 2013. The increase is primarily attributable to an increase in vendor expenses to support the revenue growth and mix shifts in type of service provided to customers.

 

Gross margin percentage for the CES segment decreased from 25.3% in the third quarter of 2013 to 21.3% in the same period of 2014. The decrease was primarily due to a higher level of vendor expenses on supported equipment. Gross margin percentage will fluctuate based on the variability of third-party vendor expenses in our 360 solutions and supplemental service programs.

 

Surgical Services

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

 

    

2014

    

2013

    

Change

    

% Change

 

Total revenue

 

$

14,887 

 

$

14,084 

 

$

803 

 

5.7 

%  

Cost of revenue

 

 

7,982 

 

 

7,921 

 

 

61 

 

0.8 

 

Medical equipment depreciation

 

 

1,426 

 

 

1,125 

 

 

301 

 

26.8 

 

Gross margin

 

$

5,479 

 

$

5,038 

 

$

441 

 

8.8 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross margin %

 

 

36.8 

%  

 

35.8 

%  

 

 

 

 

 

 

Total revenue in the SS segment increased $0.8 million, or 5.7% , to $14.9 million in the third quarter of 2014 as compared to the same period of 2013. The increase was driven by organic growth in our surgical services business.

 

Total cost of revenue in the segment increased $0.1 million, or 0.8% , to $8.0 million in the third quarter of 2014 as compared to the same period of 2013. The increase was primarily attributable to an increase in employee related costs to support growth in our surgical services business.

 

Medical equipment depreciation increased $0.3 million, or 26.8% , to $1.4 million in the third quarter of 2014 as compared to the same period of 2013. The increase was primarily due to additional medical equipment purchased .  

 

Gross margin percentage for the SS segment increased from 35.8% in the third quarter of 2013 to 36.8% in the same period of 2014. The increase in gross margin percentage was primarily driven by both higher leverage from volume growth and some shift to higher margin modalities.

 

32


 

Table of Contents

Selling, General and Administrative and Interest Expense

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

 

    

2014

    

2013

    

Change

    

% Change

 

Selling, general and administrative

 

$

26,539 

 

$

27,070 

 

$

(531)

 

(2.0)

%

Interest expense

 

 

13,264 

 

 

13,834 

 

 

(570)

 

(4.1)

 


*Not meaningful

 

Selling, General and Administrative

 

Selling, general and administrative expense decreased $0.5 million, or 2.0% , to $26.5 million for the third quarter of 2014 as compared to the same period of 2013. The decrease was primarily due to decreases in payroll and incentive expenses.

 

Selling, general and administrative expense as a percentage of total revenue was 24.9% and 26.0% for the quarter ended September 30, 2014 and 2013, respectively.

 

Interest Expense

 

Interest expense decreased $0.6 million to $13.3 million for the third quarter of 2014 as compared to the same period of 2013. This decrease was mainly attributable to the decrease in amortization of deferred financing costs combined with an increase in amortization of bond premium.

 

Income Taxes

 

Income taxes were an expense of $0.2 and a benefit of $1.3 million for the three months ended September 30, 2014 and 2013, respectively. The tax expense for the three months ended September 30, 2014 primarily relates to state minimum fees. The tax benefit for the three months ended September 30, 2013 primarily related to the reversal of a long-term liability created as a reserve against operating losses from an acquisition in 2011. The Company will continue to incur deferred tax expense in the future as tax amortization occurs. The expected tax benefit from operating loss during the three months ended September 30, 2014 was offset by the recording of additional valuation allowance. In future reporting periods, we will continue to assess the likelihood that deferred tax assets will be realizable.

 

Consolidated Net Loss

 

Consolidated net loss increased $1.2 million to $10.2 million in the third quarter of 2014 as compared to the same period of 2013.  Net loss was impacted primarily by the tax benefit recorded in the third quarter of 2013.

 

Consolidated Results of Operations for the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013

 

Total Revenue

 

Total revenue for the nine months ended September 30, 2014 was $329.2 million, compared to $321.6 million for the nine months ended September 30, 2013, an increase of $7.6 million or 2.3% .  The increase was primarily due to additional revenue in our MES segment related to growth in our 360 solutions of $12.1 million, partially offset by a decrease in peak need usage revenue of $5.6 million and the decline in NPWT device rental and disposable sales due to the interruption of Smith & Nephew commercial distribution of the RENASYS product line.

 

Cost of Revenue

 

Total cost of revenue for the nine months ended September 30, 2014 was $232.8 million compared to $222.9 million for the nine months ended September 30, 2013, an increase of $9.9 million or 4.4% . The increase was primarily in our MES segment due to an increase in 360 solutions cost of $6.7 million corresponding with the 360 solutions revenue growth

33


 

Table of Contents

and an impairment charge of $2.0 million primarily due to the planned sale of certain pumps and under-utilized patient handling equipment.

 

Gross Margin

 

Total gross margin for the nine months ended September 30, 2014 was $96.4 million, or 29.4% of total revenues, compared to $98.7 million, or 30.7% of total revenues, for the nine months ended September 30, 2013, a decrease of $2.3 million or 2.4% .  The decrease in gross margin as a percent of revenue was primarily impacted by business mix with CES growth and the reduction in NPWT device rental and asset impairment charges.

 

Medical Equipment Solutions

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

 

    

2014

    

2013

    

Change

    

% Change

 

Total revenue

 

$

216,771 

 

$

215,141 

 

$

1,630 

 

0.8 

%  

Cost of revenue

 

 

97,919 

 

 

94,918 

 

 

3,001 

 

3.2 

 

Medical equipment depreciation

 

 

51,843 

 

 

50,620 

 

 

1,223 

 

2.4 

 

Gross margin

 

$

67,009 

 

$

69,603 

 

$

(2,594)

 

(3.7)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross margin %

 

 

30.9 

%  

 

32.4 

%  

 

 

 

 

 

 

Total revenue in the MES segment increased $1.6 million, or 0.8% , to $216.8 million in the first nine months of 2014 as compared to the same period of 2013.  The increase was primarily due to growth in our 360 solutions from both new programs and expansion of existing programs of $12.1 million, partially offset by decreases in peak need usage revenue of $5.6 million and the decline in NPWT device rental   and disposable sales due to the interruption of Smith & Nephew commercial distribution of the RENASYS product line. Many of our 360 Solution customers utilize more than one of our equipment management program offerings in areas such as infusion, patient handling, and negative pressure wound therapy. As of September 30, 2014, we had 203 such active programs, up from 181 as of December 31, 2013. Peak need usage revenue was negatively impacted by soft patient census, rate concessions, and, to a lesser extent, conversion of customers to 360 solutions.

 

Total cost of revenue in the segment increased $3 million, or 3.2% , to $97.9 million in the first nine months of 2014 as compared to the same period of 2013.  This increase is due to an increase in costs to support growth in our 360 solutions of $6.7 million largely due to an increase in employee related expense of $4.2 million and an increase in repairs and maintenance and service costs for certain program offerings, partially offset by lower cost of disposables.

 

Medical equipment depreciation increased $1.2 million, or 2.4% , to $51.8 million in the first nine months of 2014 as compared to the same period of 2013. The increase in medical equipment depreciation was primarily due to an impairment charge of $ 2.0 million taken on excess infusion equipment sold in the second quarter of 2014 and under-utilized patient handling equipment charge, offset by reduced depreciation rate resulting from impairment and disposals of certain medical equipment.

 

Gross margin percentage for the MES segment decreased from 32.4% in the first nine months of 2013 to 30.9% in the same period of 2014. This decrease was primarily attributable to the increase in depreciation related to the impairment charges. Gross margin rate was also impacted by the growth in our 360 solutions, which has a lower margin rate than other medical equipment solutions.

 

Future revenue will be negatively impacted by the loss of revenues resulting from the pending FDA 510(k) clearances on RENASYS NPWT product line and the loss of the agreement related to a national GPO.

 

34


 

Table of Contents

Clinical Engineering Solutions

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

 

    

2014

    

2013

    

Change

    

% Change

 

Total revenue

 

$

68,505 

 

$

65,000 

 

$

3,505 

 

5.4 

%  

Cost of revenue

 

 

54,454 

 

 

50,120 

 

 

4,334 

 

8.6 

 

Gross margin

 

$

14,051 

 

$

14,880 

 

$

(829)

 

(5.6)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross margin %

 

 

20.5 

%  

 

22.9 

%  

 

 

 

 

 

 

Total revenue in the CES segment increased $3.5 million, or 5.4% , to $68.5 million in the first nine months of 2014 as compared to the same period of 2013. The increase was primarily due to growth in our managed 360 solutions partially offset by rate concessions. As of September 30, 2014, we had 360 solutions implemented in 142 programs in our CES segment, up from 131 programs as of December 31, 2013 .

 

Total cost of revenue in the segment increased $4.3 million, or 8.6% , to $54.5 million in the first nine months of 2014 as compared to the same period of 2013. The increase is primarily attributable to increases in employee related costs and vendor expenses to support the revenue growth and mix shifts in type of service provided to customers.

 

Gross margin percentage for the CES segment decreased from 22.9% in the first nine months of 2013 to 20.5% in the same period of 2014. The decrease was primarily due to a higher level of employee related costs and vendor expenses on supported equipment. Gross margin percentage will fluctuate based on the variability of third-party vendor expenses in our 360 solutions and supplemental service programs.

 

Surgical Services

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

 

    

2014

    

2013

    

Change

    

% Change

 

Total revenue

 

$

43,890 

 

$

41,486 

 

$

2,404 

 

5.8 

%  

Cost of revenue

 

 

24,418 

 

 

23,175 

 

 

1,243 

 

5.4 

 

Medical equipment depreciation

 

 

4,153 

 

 

4,050 

 

 

103 

 

2.5 

 

Gross margin

 

$

15,319 

 

$

14,261 

 

$

1,058 

 

7.4 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross margin %

 

 

34.9 

%  

 

34.4 

%  

 

 

 

 

 

 

Total revenue in the SS segment increased $2.4 million, or 5.8% , to $43.9 million in the first nine months of 2014 as compared to the same period of 2013. The increase was driven by organic growth in our surgical services business.

 

Total cost of revenue in the segment increased $1.2 million, or 5.4% , to $24.4 million in the first nine months of 2014 as compared to the same period of 2013. The increase was primarily attributable to an increase in employee-related costs to support growth in our surgical services business of $0.8 million.

 

Medical equipment depreciation increased $0.1 million, or 2.5% , to $4.2 million in the first nine months of 2014 as compared to the same period of 2013.

 

Gross margin percentage for the SS segment increased from 34.4% in the first nine months of 2013 to 34.9% in the same period of 2014. The increase in gross margin percentage was primarily attributable to higher leverage from volume growth and some shift to higher margin modalities.

 

35


 

Table of Contents

Selling, General and Administrative, Restructuring, Acqu i sition and Integration Expenses, Loss on Ex tinguishment of Debt and Interest Expense

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

 

    

2014

    

2013

    

Change

    

% Change

 

Selling, general and administrative

 

$

85,416 

 

$

87,246 

 

$

(1,830)

 

(2.1)

%

Restructuring, acquisition and integration expenses

 

 

1,820 

 

 

236 

 

 

1,584 

 

*

 

Intangible asset impairment charge

 

 

34,900 

 

 

 

 

34,900 

 

*

 

Loss on extinguishment of debt

 

 

 

 

1,853 

 

 

(1,853)

 

*

 

Interest expense

 

 

39,922 

 

 

41,657 

 

 

(1,735)

 

(4.2)

 


*Not meaningful

 

Selling, General and Administrative

 

Selling, general and administrative expense decreased $1.8 million, or 2.1% , to $85.4 million for the first nine months of 2014 as compared to the same period of 2013. The decrease was primarily due to a decrease in consulting expense, bad debt and payroll related expenses.

 

Selling, general and administrative expense as a percentage of total revenue was 25.9% and 27.1% for the nine months ended September 30, 2014 and 2013, respectively.

 

Restructuring, Acquisition and Integration Expenses

 

Restructuring, acquisition and integration expenses increased $1.6 million for the first nine months of 2014 as compared to the same period of 2013. The increase was primarily due to additional charges to realign the management team.

 

Intangible Asset Impairment Charge

 

During the second quarter of 2014, the Company became aware that future financial results of the Company will be negatively impacted by the loss of revenues resulting from pending FDA 510(k) clearances on RENASYS NPWT product line and the loss of the agreement related to a national GPO. The Company applies a fair value based impairment test to the net book value of goodwill and intangible assets with indefinite lives on an annual basis and on an interim basis if events or circumstances indicate that an impairment loss may have occurred. The review of indefinite-life intangibles for impairment during the second quarter of 2014 indicated that the carrying value of trade names in the MES segment exceeded its estimated fair values. As a result, the Company performed an interim impairment test and recorded a preliminary non-cash impairment charge of $34.9 million during the second quarter of 2014. The calculation of the preliminary impairment charge contains significant judgments and estimates including weighted average cost of capital, future revenue, profitability, cash flows and fair values of assets and liabilities. The finalization of the second quarter impairment charge and the result of the third quarter impairment review resulted in no changes to the second quarter preliminary charge.  

 

Loss on Extinguishment of Debt

 

For the nine months ended 2013, we wrote off $1.9 million of unamortized deferred financing costs related to redemption of our floating rate notes.

 

Interest Expense

 

Interest expense decreased $1.7 million to $39.9 million for the first nine months of 2014 as compared to the same period of 2013. This decrease was mainly attributable to the decrease in amortization of deferred financing costs combined with an increase in amortization of bond premium.

 

36


 

Table of Contents

Income Taxes

 

Income taxes were a benefit of $13.2 and $0.4 million for the nine months ended September 30, 2014 and 2013, respectively. The tax benefit for the nine months ended September 30, 2014 primarily relates to intangible asset impairment charge, partially offset by state minimum fees. The tax benefit for the nine months ended September 30, 2013 primarily relates to two items along with state minimum fees. The first item was to record a deferred tax liability for adjustments in connection with the tax amortization of indefinite-life goodwill. The second item was to reverse a long-term liability created as a reserve against operating losses from an acquisition in 2011. The Company will continue to incur deferred tax expense in the future as tax amortization occurs. The expected tax benefit from operating loss during the nine months ended September 30, 2014 was offset by the recording of additional valuation allowance. In future reporting periods, we will continue to assess the likelihood that deferred tax assets will be realizable.

 

Consolidated Net Loss

 

Consolidated net loss increased $20.6 million to $52.4 million in the first nine months of 2014 as compared to the same period of 2013. Net loss was impacted primarily by the intangible asset impairment charge recorded in the second quarter of 2014.

 

EBITDA

 

Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) was $84.6 and $82.4 million for the nine months ended September 30, 2014 and 2013, respectively.  EBITDA for the nine months ended September 30, 2014, was impacted by growth in our SS segment combined with lower selling, general and administrative expenses and a decrease in loss on extinguishment of debt, partially offset by an increase in restructuring expense.

 

Future cash flows from operations will be negatively impacted by the loss of revenues resulting from the pending FDA 510(k) clearances on RENASYS NPWT product line and the loss of agreement related to a national GPO.

 

In addition to using EBITDA internally as a measure of operational performance, we disclose it externally to assist analysts, investors and lenders in their comparisons of operational performance, valuation and debt capacity across companies with differing capital, tax and legal structures. EBITDA, however, is not a measure of financial performance under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to, or more meaningful than, net income as a measure of operating performance or to cash flows from operating, investing or financing activities or as a measure of liquidity.  Since EBITDA is not a measure determined in accordance with GAAP and is thus susceptible to varying interpretations and calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. EBITDA does not represent an amount of funds

37


 

Table of Contents

that is available for management’s discretionary use. A reconciliation of net loss attributable to UHS to EBITDA is included below:

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

 

September 30,

 

(in thousands)

    

2014

    

2013

 

Net loss attributable to Universal Hospital Services, Inc.

 

$

(52,811)

 

$

(32,382)

 

Interest expense

 

 

39,922 

 

 

41,657 

 

Benefit for income taxes

 

 

(13,232)

 

 

(398)

 

Depreciation, assets impairment and amortization of intangibles

 

 

75,860 

 

 

73,570 

 

Intangible asset impairment charge

 

 

34,900 

 

 

 

EBITDA

 

$

84,639 

 

$

82,447 

 

 

 

 

 

 

 

 

 

Other Financial Data:

 

 

 

 

 

 

 

Net cash provided by operating activities

 

$

35,277 

 

$

35,478 

 

Net cash used in investing activities

 

 

(41,223)

 

 

(45,149)

 

Net cash provided by financing activities

 

 

5,946 

 

 

9,671 

 

 

 

 

 

 

 

 

 

Other Operating Data (as of end of period):

 

 

 

 

 

 

 

Medical equipment (approximate number of owned outsourcing units)

 

 

269,000 

 

 

274,000 

 

District service centers

 

 

84 

 

 

83 

 

SS stand-alone service centers

 

 

 

 

 

Centers of Excellence

 

 

 

 

 

 

SEASONALITY

 

Quarterly operating results are typically affected by seasonal factors.  Historically, our first and fourth quarters are the strongest, reflecting increased customer utilization during the fall and winter months.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Original Notes and Add-on Notes — 7.625%. On August 7, 2012, we issued $425.0 million in aggregate principal amount of 7.625% Second Lien Senior Secured Notes due 2020 (the “Original Notes”) under an indenture dated as of August 7, 2012 (the “2012 Indenture”).   On February 12, 2013, we issued $220.0 million in aggregate principal amount of 7.625% Second Lien Senior Secured Notes due 2020 (the “Add-on Notes”, and along with the Original Notes, the “2012 Notes”) as “additional notes” pursuant to the 2012 Indenture . The 2012 Notes mature on August 15, 2020.

 

The 2012 Indenture provides that the 2012 Notes are our second lien senior secured obligations and are fully and unconditionally guaranteed on a second lien senior secured basis by our existing and certain of our future 100%-owned domestic subsidiaries.

 

Our principal sources of liquidity are expected to be cash flows from operating activities and borrowings under our senior secured credit facility, which provides for loans in an amount of up to $235.0 million, subject to our borrowing base. See Note 8, Long-Term Debt for details related to our senior secured credit facility. It is anticipated that our principal uses of liquidity will be to fund capital expenditures related to purchases of medical equipment, provide working capital, meet debt service requirements and finance our strategic plans.

 

We require substantial cash to operate our medical equipment solutions programs and service our debt.  Our outsourcing programs require us to invest a significant amount of cash in medical equipment purchases.  To the extent that such expenditures cannot be funded from our operating cash flow, borrowing under our senior secured credit facility or other financing sources, we may not be able to conduct our business or grow as currently planned.

 

If we are unable to generate sufficient cash flow from operations in order to service our debt, we will be forced to take actions such as reducing or delaying capital expenditures, selling assets, restructuring or refinancing our debt, or seeking additional equity capital.  This, to a certain extent, is subject to general economic, financial, competitive, legislative,

38


 

Table of Contents

regulatory and other factors that are beyond our control.  If we are unable to repay our debt at maturity, we may have to obtain alternative financing, which may not be available to us.

 

Future cash flows from operations will be negatively impacted by the loss of revenues resulting from the pending FDA 510(k) clearances on RENASYS NPWT product line and the loss of the agreement related to a national GPO.

 

Net cash provided by operating activities was $35.3 and $35.5 million for the nine months ended September 30, 2014 and 2013, respectively.

 

Net cash used in investing activities was $41.2 and $45.1 million for the nine months ended September 30, 2014 and 2013, respectively.  The decrease in net cash used in investing activities was primarily due to higher proceeds from sale of medical equipment , partially offset by higher medical equipment purchases to support the growth in 360 solutions during 2014 compared to the same period of 2013.

 

Net cash provided by financing activities was $5.9 and $9.7 million for the nine months ended September 30, 2014 and 2013, respectively.  The decrease in net cash provided by financing activities was primarily due to lower net borrowings in 2014 compared to the same period of 2013.

 

Based on the level of operating performance expected in 2014, we believe our cash from operations and additional borrowings under our senior secured credit facility, will meet our liquidity needs for the foreseeable future, exclusive of any borrowings that we may make to finance potential acquisitions.  However, if during that period or thereafter we are not successful in generating sufficient cash flows from operations or in raising additional capital when required in sufficient amounts and on terms acceptable to us, our business could be adversely affected.  As of September 30, 2014, we had $129.4 million of availability under the senior secured credit facility based on a borrowing base of $182.2 million less borrowings of $49.2 million and after giving effect to $3.6 million used for letters of credit.  As of September 30, 2013, we had $143.4 million of availability under the senior secured credit facility based on a borrowing base of $191.8 million less borrowings of $44.2 million and after giving effect to $4.2 million used for letters of credit.

 

Our levels of borrowing are further restricted by the financial covenants set forth in our senior secured credit facility agreement and the 2012 Indenture governing our 2012 Notes, as described in Note 8, Long-Term Debt.

 

The Company was in compliance with all financial covenants for all periods presented.

 

RECENT ACCOUNTING PRONOUNCEMENT

 

See Item 1 of Part I, Note 2, Recent Accounting Pronouncements.

 

SAFE HARBOR STATEMENT

 

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: We believe statements in this Quarterly Report on Form 10-Q looking forward in time involve risks and uncertainties.  The following factors, among others, could adversely affect our business, operations and financial condition, causing our actual results to differ materially from those expressed in any forward-looking statements:

 

·

our competitors’ activities;

·

our customers’ patient census or service needs;

·

global economic conditions’ effect on our customers;

·

our ability to maintain existing contracts or contract terms and enter new contracts with customers;

·

uncertainties as to the effect of non-renewal of existing contracts;

·

consolidation in the health care industry and its effect on prices;

·

our relationships with key suppliers;

·

our ability to change the manner in which health care providers procure medical equipment;

·

the absence of long-term commitments and cancellations by or disputes with customers;

·

our dependence on key personnel;

·

our ability to identify and manage acquisitions;

·

increases in expenses related to our pension plan;

39


 

Table of Contents

·

our cash flow fluctuation;

·

the increased credit risks associated with doing business with home care providers and nursing homes;

·

the risk of claims associated with medical equipment we outsource and service;

·

increases costs we cannot pass through;

·

the failure of any management information system;

·

the inherent limitations on internal controls of our financial reporting;

·

the uncertainty surrounding health care reform initiatives;

·

the federal Privacy law risks;

·

the federal Anti-Kickback law risks;

·

changes to third-party payor reimbursement for health care items and services;

·

potential other new healthcare laws or regulations;

·

our customers operate in a highly regulated environment;

·

our fleet’s risk of recalls or obsolescence;

·

our substantial debt service obligations;

·

our need for substantial cash to operate and expand our business as planned; and

·

our history of net losses and s ubstantial interest expense.

 

For further information on risk applicable to us, please see the disclosure regarding the risk factors as set forth in Item 1A of Part II of this Quarterly Report on Form 10-Q.

 

Item 3.  Quantitative and Qualitative Disclosures about Market Risk

 

We are exposed to market risk arising from adverse changes in interest rates, fuel costs and pension valuation.  We do not enter into derivatives or other financial instruments for speculative purposes.

 

Interest Rates

 

We use both fixed and variable rate debt as sources of financing.  At September  30, 2014, we had approximately $ 721.6 million of total debt outstanding of which $ 49.2 million was bearing interest at variable rates. Based on variable debt levels at September  30, 2014, a 1.0 percentage point change in interest rates on variable rate debt would have resulted in annual interest expense fluctuating by approximately $ 0.5 million.

 

Fuel Costs

 

We are also exposed to market risks related to changes in the price of gasoline used to fuel our fleet of delivery and sales vehicles.  A hypothetical 10% increase in the first nine months of 2014 average price of unleaded gasoline, assuming gasoline usage levels for the nine months ended September  30, 2014, would lead to an annual increase in fuel costs of approximately $ 0.6 million.

 

Pension

 

Our pension plan assets, which were approximately $ 19.6 million at December 31, 2013, are subject to volatility that can be caused by fluctuations in general economic conditions. Continued market volatility and disruption could cause further declines in asset values, and if this occurs, we may need to make additional pension plan contributions and our pension expense in future years may increase. A hypothetical 10% decrease in the fair value of plan assets at December 31, 2013 would lead to a decrease in the funded status of the plan of approximately $ 2.0 million.

 

Other Market Risk

 

As of September  30, 2014, we have no other material exposure to market risk.

 

Item 4.  Controls and Procedures

 

(a)

Evaluation of disclosure controls and procedures

 

40


 

Table of Contents

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934 as amended (the “Exchange Act”)) as of the end of the period covered by this report.  Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of September  30, 2014.

 

(b)

Changes in internal control over financial reporting

 

There were no changes that occurred during the most recent fiscal quarter that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

The Company, in the ordinary course of business, could be subject to liability claims related to employees and the equipment that it rents and services. Asserted claims are subject to many uncertainties and the outcome of individual matters is not predictable. While the ultimate resolution of these actions may have an impact on the Company’s financial results for a particular reporting period, management believes that any such resolution would not have a material adverse effect on the financial position, results of operations or cash flows of the Company and the chance of a negative outcome on outstanding litigation is considered remote. See the additional information in Item 1 of Part I, Note 9, Commitments and Contingencies.

 

Item 1A.  Ris k Factors

 

Our business is subject to various risks and uncertainties.  Any of the risks discussed elsewhere in this Quarterly Report on Form 10-Q or our other filings with the Securities and Exchange Commission, including the risk factors set forth in our 2013 Annual Report on Form 10-K, could materially adversely affect our business, financial condition or results of operations.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

On October 24, 2014, the Company reported in a Current Report on Form 8-K that Timothy W. Kuck resigned from his position as  Executive Vice President, Strategy and Business Development of the Company effective November 1, 2014.  In connection with his resignation, Mr. Kuck has entered into a mutual termination agreement (“MTA”) with the Company effective November 1, 2014.  This MTA includes customary non-competition and release provisions in exchange for separation payments totaling approximately $346,245 along with other benefits.  In addition, Mr. Kuck will receive a payment totaling approximately $232,291, which represents a pro-rated portion of the incentive compensation for the fiscal year ending December 31, 2014 for which he was eligible under the terms of the Company’s Executive Incentive Program (“EIP”), to be paid in accordance with the Company’s normal year-end procedure.  The EIP is described in the Company’s Form 10-K for the fiscal year ended December 31, 2013.  The foregoing description of the terms of Mr. Kuck’s  MTA is qualified by reference to the text of the MTA, a copy of which is filed as Exhibit 10.1 to this Form 1 0- Q .

41


 

Table of Contents

 

Effective November 4 , 2014, the Compensation Committee of our Board of Directors recommended, and the board of directors (the “Parent Board”) of UHS Holdco, Inc., our parent company ( “Parent”), approved, an amendment (the “Amendment”) to the Parent’s 2007 Stock Option Plan (the “2007 Stock Option Plan”) to remove the 2007 Stock Option Plan’s mandator y ten year limit on the duration of stock options. In addition, the Compensation Committee recommended, and the Parent Board approved, unilateral amendments to certain outstanding stock option agreements . These amendments extend the expiration date of such options to November 4 , 202 4 and reset the option exercise price at $0.71 per share, which was the fair market value of Parent’s common stock on the amendment date as determined by a third party valuation obtained by the Parent Board. The orig inal options were granted from June 18, 2007 to May 21, 2013 with exercise prices ranging from $1.00 to $1.83. The Amendment to the 2007 Stock Option Plan and the amendments to the individual options do not change the number of options granted, the vesting commencement date, the vesting schedules or any continued service requirements. The amendment will result in additional stock compensation expense estimated at $2 to $3 million, of which approxima tely $1 million will be recognized in 2014.  The foregoing description of the Amendment to the 2007 Stock Option Plan and amendments of individual options is not complete and is qualified in its entirety by reference to the full text of the Amendment and form of notice to option holders, a copy of each of which is filed as Exhibit 10.2 and Exhibit 10.3, respectively, to this Form 10-Q.

 

 

Item 6. Exhibits

 

 

 

 

Number

 

Description

 

 

 

10.1 

 

Mutual Termination Agreement and Release, dated November 1 , 2014, between Timothy W. Kuck and Universal Hospital Services, Inc.

 

 

 

10.2 

 

2007 Stock Option Plan, as amended and restated November 4 , 2014.

 

 

 

10.3 

 

For m of notice to option holders regarding amendments to outstanding options.

 

 

 

31.1 

 

Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

31.2 

 

Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.1 

 

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.2 

 

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101 

 

Financial Statements from the Quarterly Report on Form 10-Q of the Company for the quarter ended September  30, 2014, formatted in Extensible Business Reporting Language: (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Loss, (iv) the Consolidated Statements of Cash Flows and (v) the Notes to Consolidated Financial Statements.

 

 

42


 

Table of Contents

 

SIGNATU RES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: November 6 , 2014

 

 

 

 

Universal Hospital Services, Inc.

 

 

 

By

/s/ Gary D. Blackford

 

Gary D. Blackford,

 

Chairman of the Board and Chief Executive Officer

 

(Principal Executive Officer and Duly Authorized Officer)

 

 

 

By

/s/ James B. Pekarek

 

James B. Pekarek

 

Executive Vice President and Chief Financial Officer

 

(Principal Financial Officer)

 

43


 

 

PICTURE 7

 

Personal and Confidential

 

 

Date: October 13 , 2014

 

To: Tim Kuck  

 

SUBJECT: Mutual Termination Agreement and Release

 

This Mutual Termination Agreement and Release (“Agreement and Release”) between Universal Hospital Services, Inc. (hereinafter “UHS”) and you relat es to your termination from employment with UHS , which will be effective on November 1, 20 14   (“Termination Date”).  The purpose of this Agreement and Release is to set forth the terms of your separation from employment with UHS.

 

1.

Regular Separation Terms 

 

In connection with your employment termination, you have the following rights and options:

 

a.

Salary.  You will receive your current base pay through the Termination Date, in accordance with UHS’ normal payroll practices. 

 

b.

PTO You will receive a lump sum payment for your accrued and unused PTO balance as of your Termination Date.  This amount will be paid on or about November 14 , 2014   and is subject to all applicable withholding deductions .

 

c.

Medical and Dental Coverage.  Effective the first day of the month following your Termination Date, you may elect at your expense to continue group health and dental benefits through the Consolidated Omnibus Budget Reconciliation Act (“COBRA”) for a period of up to 18 months, to the extent you are eligible, subject to the Enhanced Separation Terms below. You will separately receive the appropriate COBRA application form and rates from Optum Health Financial Corporat ion within 30 days of your T ermination D ate. You may contact Optum directly at 800-588-2020.

 

d.

Life Insurance.  Your company-paid life insurance remains in effect after your Termination Date until the end of that month .  Effective the first day of the month following your Termination Date, you may elect at your expense to continue such life insurance by paying premiums yourself directly to Optum

 

 

IND  - 052209 Confidential Mutual Termination Agreement and Release

1


 

 

e.

Disability Insurance.  Your short-term and long-term disability benefits end at midnight on your Termination Date.  No conversion to an individual policy is provided for either coverage.

 

f.

Long Term Savings Plan.  If you are a participant in the Long Term Savings Plan, your active participation in that Plan will end on your Termination Date.  Within 60 days from your Termination Date, you will receive a termination packet from Fidelity, which provides detailed information with regard to your account.  You may also contact Fidelity directly at 800-835-5097.  You have access to your account 24 hours a day at www.401k.com for automated transactions or to request a distribution.  We encourage you to seek competent tax advice to fully understand the tax consequences applicable to your distribution options.

 

g.

Pension.  If you are eligible for pension benefits under the UHS Employee’s Pension Plan, your pension benefit information will be sent to you within 60 days from your Termination Date.  

 

2.

Enhanced Separation Benefits 

 

If you sign and return this Agreement and Release and you do not rescind or breach this Agreement and Release, UHS will provide you with the following additional payments and benefits, which exceed the nature and scope of those to which you would otherwise be entitled and which you acknowledge and agree constitute adequate consideration for your promises herein .  The process for accepting and rescinding the terms of this Agreement and Release is set forth in sections 4 and 5 below.

 

a.

Severance Pay Under the terms of the UHS Severance Plan, y ou will receive $331,844.98 representing 52 weeks of severance pay at your current base pay.     Such amount will be paid out of payroll on a bi-weekly basis and is subject to applicable withholding deductions.  UHS will begin making such p ayments   a s soon as practicable following the effectiveness of the release described in section 3 below. 

b.

Incentive Pay .  Under the terms of the UHS Executive Severance Plan, you will receive $232,290.80.  Such incentive payment will be payable in 2015 at the time annual incentive payments are paid to other UHS executives , but in no event later than April 17, 2015 .

c.

Medical and Dental Premiums.     As noted above, you may elect at your expense to continue group health and dental benefits under COBRA for up to 18 months to the extent that you are eligible UHS will pay you $14,400 in a lump sum, which is equivalent to   12 months of COBRA continuation coverage and is subject to applicable withholding deductions UHS will make such payment a s soon as practicable following the effectiveness of the release described in section 3 below.  This one-time lump sum payment is a separate payment from the severance pay described in Section 2(a) above and is intended to be exempt from Code Section 409A under the short-term deferral rule.

 

d.

Outplacement Assistance.  Career transition and planning services will be provided through Challenger, Gray & Christmas and paid for by UHS at the twelve-month Professional Management Services level, provided you execute this Agreement and Release without rescission.  Such services must be completed within 12 months  

IND  - 052209 Confidential Mutual Termination Agreement and Release

2


 

 

following your Termination Date.  Contact Challenger, Gray & Christmas at 312-332-5790 for more information on career transition services.

 

e.

Deductions .  Normal deductions which UHS is obligated by law to deduct, or which UHS in good faith believes it is obligated by law to deduct, will be deducted by UHS from any payments made or to be made by UHS under this Agreement and Release.

 

3.

Release of Claims

 

In exchange for receiving payments and other consideration as described, you agree on your own behalf and on behalf of anyone claiming rights through you, to fully and finally release, waive and forever discharge UHS, its affiliates, successors, past and present officers, directors, committees, employees, insurers, agents, attorneys, associates and employee benefit plans (collectively “Released Parties”) from all claims, demands or causes of action arising out of facts or occurrences before and as of the date of this Agreement and Release, whether known or unknown to you; however, you are not prohibited from pursuing claims for any employee benefit vested and accrued in your favor as of your Termination Date. 

 

You agree that this Agreement and Release is intended to be broadly construed so as to resolve any pending and potential disputes between you and the Released Parties that you have up to the date of your acceptance of this Agreement and Release, whether such disputes are known or unknown to you, including, but not limited to, claims based on express or implied contract; any administrative agency action or proceeding to the extent allowed by law; any action arising in tort, including, but not limited to interference with contractual or business relationships, breach of fiduciary duty, promissory or equitable estoppel, invasion of privacy, libel, slander, defamation, intentional infliction of emotional distress, or negligence; any or all claims for wrongful discharge, breach of a covenant of good faith and fair dealing; and any and all claims including but not limited to those based on the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, Title VII of the Civil Rights Act, the Civil Rights Act of 1991, the Employment Retirement Income Security Act, the Family and Medical Leave Act, the Americans With Disabilities Act, the State of Minnesota   Human Rights Act ,   other applicable state human rights laws and any other applicable federal, state, local or foreign  law, regulation, ordinance or order.  The above release of claims does not include any claims that the law does not allow to be waived or any claims that may arise after the date you sign this Agreement and Release, nor does it prohibit you from filing any charge or complaint with, or participating in any investigation or proceeding conducted by, the Equal Employment Opportunity Commission (“EEOC”).  Notwithstanding the foregoing, you release and waive any right you may have to obtain monetary relief or compensation awarded by the EEOC.  You further agree to not voluntarily assist or participate in any lawsuits brought by other individuals against UHS, unless such assistance is requested by UHS .

IND  - 052209 Confidential Mutual Termination Agreement and Release

3


 

 

 

4 . Acceptance of this Agreement and Release

 

You acknowledge that, before signing this Agreement and Release, you were given a period of at least 21 days from the date of receipt of this Agreement and Release to consider it.  To accept the terms of this Agreement and Release, you must sign and date it within the 21 -day consideration period or by the end of the workday on your Termination Date, whichever is later.  You may not sign this Agreement and Release before your Termination Date.  After you have signed and dated this Agreement and Release, you must send or return it to UHS by hand or by mail within the 21 -day period that you have to consider it.  Any changes to this Agreement and Release whether material or not will not restart the running of the 21 -day period. 

 

To accept this Agreement and Release, sign and return it to   Bob Creviston, Chief Human Resources Officer ,   Universal Hospital Services, Inc ., 6625 West 78 th Street, Suite 300, Minneapolis, MN 55439

 

If you choose to return this Agreement and Release by mail, it must be properly addressed and postmarked within the 21 -day consideration period and sent by certified mail, return receipt requested, first-class postage prepaid.

 

If you sign this Agreement and Release before the end of the 21 -day consideration period, it will be your voluntary decision to do so because you have decided that you do not need any additional time to decide whether to sign it.   You waive any right you might have to additional time beyond the 21- day consideration period within which to consider this Agreement and Release.

 

You have been advised by UHS to consult with an attorney before signing this Agreement and Release and this sentence constitutes such advice in writing.

 

5.

Rescission of this Agreement and Release 

 

At any time for a period of 15 days after you have signed this Agreement and Release (not counting the day you signed it), you may rescind it.  This Agreement and Release will not become effective or enforceable until the 15-day rescission period has expired without you rescinding it.  To rescind your acceptance, you must send by mail or hand-deliver a written, signed statement of rescission of your acceptance to UHS within the 15-day rescission period. Any statement of recession of acceptance must be directed to Bob Creviston ,   Chief Human Resources Officer , Universal Hospital Services, Inc., 6625 West 78 th Street, Suite 300, Minneapolis, MN 55439 .  If you choose to return it by mail, it must be properly addressed and postmarked within 15 days after you signed the Agreement and Release and sent by certified mail, return receipt requested, first-class postage prepaid.

 

 

6. Outstanding Obligations

 

You agree that before your Termination Date, you will satisfy all outstanding personal obligations associated with your employment with UHS, including, but not limited to,

IND  - 052209 Confidential Mutual Termination Agreement and Release

4


 

 

outstanding expense reports and travel advances, and the balance on any company credit card you hold.

 

Before the end of your Termination Date, unless otherwise agreed to, you must return to UHS all company property, including without limitation, any cellular telephone, pagers, PDA, laptops, all computer equipment, diskettes, books and marketing material, reference material, notes, documents, customer and vendor information, keys, security cards, files and any proprietary and/or confidential information, including but not limited to confidential information relating to customer lists, employees, pricing for products and services and strategic planning information.  You must also purge all information and data relating to UHS from any home or personal computer or other electronic device, without retaining any copies of such information or data   and you agree upon request to sign and return the attached Acknowledgment of Returned Property after your Termination Date .

 

7.

Confidentiality

 

You agree that this Agreement and Release will remain confidential and will not be disclosed except to your spouse, financial advisor, legal counsel or to a prospective employer, who should be advised only on a need to know basis, or as may be required by law or in any legal proceeding to enforce your rights hereunder.

 

8.

Cooperation

 

You agree to be   available to UHS, and any attorneys or agents acting on UHS’ behalf , and to cooperate in good faith with UHS, concerning any litigation or administrative claims or investigations that involv e UHS and aris e out of any incidents that occurred during your employment of which you have knowledge.

 

You agree not to incur, as an employee, any additional business expenses relating to UHS after your last day of being actively at work.  UHS agrees to reimburse you for those out of pocket business expenses relating to UHS, which you incurred on or before your last day of being actively at work, for which you have not been reimbursed to date, in accordance with UHS’ standard expense reimbursement policies and procedures.

 

You agree not to make, confirm or cause or attempt to cause any other person to make or confirm, any written or oral information about UHS, which is disparaging about UHS or which in any way reflects negatively upon UHS.  Similarly, UHS will not make, confirm or cause or attempt to cause any other person to make or confirm, any written or oral information about you, which is disparaging about you or which in any way reflects negatively upon you.  

 

Y ou agree that ,   for a period of one year after the severance p ayments end, you will not directly or indirectly influence or advise any person who is or shall be employed by or in the service of UHS to leave or decline such employment or service to compete with UHS or to enter into employment or service of any competitor of UHS.

IND  - 052209 Confidential Mutual Termination Agreement and Release

5


 

 

 

9.

Entire Agreement, Governing Law and Construction

 

This Agreement and Release contain the entire agreement between you and UHS concerning your separation from employment, severance and release of all claims; however, you and UHS agree that your obligations under the UHS Confidentiality and Non Competitions Agreements you have signed will remain in full force and effect.  You may not assign this Agreement and Release, in whole or in part, without the prior written consent of UHS.  This Agreement and Release may not be changed, except in a writing that details the change and is signed by both you and UHS.

 

This Agreement and Release will be governed and enforced solely under the laws of the State of Minnesota, without giving effect to the conflicts of law principles thereof.  If any portion of this Agreement and Release is deemed to be invalid or unenforceable, that portion will be deemed omitted and the remainder of this Agreement and Release will remaining effect. 

 

 

10.

Remedies for Breach

 

If you breach or challenge the enforceability of this Agreement and Release and do not prevail, you agree to reimburse UHS for any monetary consideration received by you pursuant to this Agreement and Release and you agree to pay the reasonable attorneys’ fees and costs that UHS incurs in enforcing this Agreement and Release; provided, however, that this provision has no applicability to claims that cannot be waived under the Age Discrimination in Employment Act, including the right to challenge whether this Agreement and Release constitutes a knowing and voluntary waiver of claims within the meaning of the Act.  Similarly, if UHS breaches or challenges the enforceability of this Agreement and Release and does not prevail, it agrees to pay the reasonable attorneys’ fees and costs that you incur in enforcing this Agreement and Release.

 

11.

Acknowledgement  

 

By my signature below, I acknowledge and certify that:

 

a. I   have read and understand all of the terms of this Agreement and Release and do not rely on any representation or statement, written or oral, not set forth in this Agreement and Release; specifically I understand that this Agreement and Release includes a waiver and release of legal rights I may have;

 

b. I have had a reasonable period of time to consider this Agreement and Release;

 

c. I am signing this Agreement and Release knowingly and voluntarily and without pressure, and after having given the matter full and careful consideration;

 

d. I have been advised to consult with an attorney of my choosing before signing this Agreement and Release and I have had the opportunity to do so ;

 

IND  - 052209 Confidential Mutual Termination Agreement and Release

6


 

 

e. I have the right to consider the terms of this Agreement and Release for at least 21   days and if I take fewer than 21 days to review this Agreement and Release, I hereby waive any and all rights to the balance of the 21 day review period;

 

f. I have the right to revoke this Agreement and Release within 15 days after signing it, by providing written notice of revocation directed to Bob Creviston ,   Chief Human Resources Officer , Universal Hospital Services, Inc., 6625 West 78 th Street, Suite 300, Minneapolis, MN 55439 .  If I revoke this Agreement and Release during this 15-day period, it becomes nu ll and void in its entirety; and

 

a.

T his Agreement and Release is not effective if it is signed b efore my Termination   Date .  

 

 

 

If you accept this Agreement and Release, please sign both copies, then return both signed original copies to Bob Creviston ,   Chief Human Resources Officer , Universal Hospital Services, Inc., 6625 West 78 th Street, Suite 300, Minneapolis, MN 55439 for countersignature.  We will send you a fully executed original for your records.

 

 

 

 

 

 

 

 

 

 

UNIVERSAL HOSPITAL SERVICES, INC.

 

AGREED TO AND ACCEPTED BY:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Gary D. Blackford

 

/s/ Timothy W. Kuck

 

 

 

 

 

 

 

 

 

 

Date:

November 1, 2014

 

Date:

November 1, 2014

 

IND  - 052209 Confidential Mutual Termination Agreement and Release

7


UHS HOLDCO, INC.
AMENDED AND RESTATED STOCK OPTION PLAN

ARTICLE I

Purpose of Plan

The Amended and Restated Stock Option Plan (the " Plan ") of UHS Holdco, Inc. (the " Company "), adopted by the Board (as defined below) and shareholders of the Company effective May 31, 2007, and amended and restated on November 4, 2014, is intended to advance the best interests of the Company by providing executives and other employees of the Company or any Subsidiary (as defined below) and certain directors and consultants of the Company, in each case, who have substantial responsibility for the management and growth of the Company or any Subsidiary with additional incentives by allowing such employees, directors and/or consultants to acquire an ownership interest in the Company.  The Plan is a compensatory benefit plan within the meaning of Rule 701 under the Securities Act of 1933, as amended (the " Securities Act ") and, unless and until the Common Stock (as defined below) is publicly traded, the issuance of stock purchase options (" Options ") for shares of Common Stock pursuant to the Plan and the issuance of shares of Common Stock pursuant to such Options is intended to qualify for the exemption from registration under the Securities Act provided by Rule 701.

ARTICLE II

Definitions

For purposes of the Plan the following terms have the indicated meanings:

" Affiliate " means, when used with reference to a specified Person, any Person that directly or indirectly controls or is controlled by or is under common control with the specified Person. As used in this definition, "control" (including, with its correlative meanings, "controlled by" and "under common control with") shall mean possession, directly or indirectly, of power to direct or cause the direction of management or policies (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise). With respect to any Person who is an individual, "Affiliates" shall also include, without limitation, any member of such individual's Family Group.

" Aggregate Repurchase Price " shall have the meaning set forth in Section 5.7(c) .

" Approved Sale " shall have the meaning set forth in Section 5.10(a) .

" Board " means the Company's Board of Directors.

" BSMB " means Bear Stearns Merchant Banking Partners III, L.P. or its Affiliates.

" Cause " means, with respect to any Participant, such Participant's (i) continued failure, whether willful, intentional or grossly negligent, after written notice, to perform substantially such Participant's duties to the Company and its Subsidiaries (the " Duties ") as


 

determined by such Participant's immediate supervisor, the Chief Executive Officer or a Senior Vice President of the Company, or the Board (other than as a result of a disability); (ii) dishonesty or fraud in the performance of such Participant's Duties or a material breach of such Participant's duty of loyalty to the Company or its Subsidiaries; (iii) conviction or confession of an act or acts on such Participant's part constituting a felony under the laws of the United States or any state thereof or a misdemeanor which materially impairs such Participant's ability to perform such Participant's Duties; (iv) willful act or omission on such Participant's part which is materially injurious to the financial condition or business reputation of the Company or any of its Subsidiaries; or (v) breach of any non ‑competition, non ‑competition, non ‑solicitation, non ‑disclosure or confidentiality agreement applicable to such Participant; provided , that if any Participant is a party to an employment agreement with the Company or its Subsidiaries, the definition of "cause" (or term of like import) contained therein, if any, shall control.

" Code " means the Internal Revenue Code of 1986, as amended.

" Committee " means the Compensation Committee or such other committee of the Board as the Board may designate to administer the Plan or, if for any reason the Board has not designated such a committee, the Board.  The Committee, if other than the Board, shall be composed of two or more directors as appointed from time to time by the Board.

" Common Stock " means the Company's Common, Stock, par value $.01 per share.

" Exchange Act " means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

" Fair Market Value " of any Common Stock as of any given date shall be determined in good faith by the Board based on such factors as the Board, in the exercise of its reasonable business judgment, considers relevant; provided , that in making such determination, the Board shall assume that the Company and its Subsidiaries are sold as a going concern and then liquidated and shall not provide for any discounts based on the fact that the Common Stock being valued represent a minority interest in the Company; provided ,   further , that notwithstanding anything herein to the contrary, any determination of Fair Market Value shall be made in accordance with the requirements of Section 409A of the Code.

" Family Group " means, when used with reference to a specified individual Person, (i) such Person's spouse, former spouse, ancestors and descendants (whether natural or adopted), parents and their descendants and any spouse of the foregoing persons (collectively, "relatives"), (ii) the trustee, fiduciary or personal representative of such Person and any trust solely for the benefit of such Person and/or such Person's relatives (other than any remainder interests) or (iii) any limited partnership or limited liability company the governing instruments of which provide that such Person shall have the exclusive, nontransferable power to direct the management and policies of such entity and of which the sole owners of partnership interests, membership interests or any other equity interests are, and will remain, limited to such Person and such Person's relatives.

" Good Reason " means, with respect to any Participant, (i) the Company or its Subsidiaries has reduced or reassigned a material portion of such Participant's duties (per such


 

Participant's job description); (ii) such Participant's base salary has been reduced other than in connection with an across ‑the ‑board reduction (of approximately the same percentage) in executive compensation to employees imposed by the Board in response to negative financial results or other adverse circumstances affecting the Company or its Subsidiaries; or (iii) the Company or its Subsidiaries has required such Participant to relocate in excess of fifty (50) miles from the location where such Participant is currently employed; provided , that if any Participant is a party to an employment agreement with the Company or its Subsidiaries, the definition of "good reason" (or term of like import) contained therein, if any, shall control.

" Independent Third Party " means any Person who, immediately prior to the contemplated transaction, does not own in excess of 5% of the Common Stock on a fully diluted basis, who is not controlling, controlled by or under common control with any such 5% owner of the Common Stock and who is not the spouse or descendant (by birth or adoption) of any such 5% owner of the Common Stock.

" IPO " means an initial Public Offering of Common Stock or the Company otherwise becoming a "reporting company" under Section 13 of the Exchange Act with regard to a registration of Common Stock under Section 12 of the Exchange Act.

" Issued Shares " means (i) all shares of Common Stock issued upon the proper exercise of an Option and (ii) all equity securities issued with respect to the Common Stock referred to in clause (i) above by way of stock dividend or stock split or in connection with any conversion, merger, consolidation or recapitalization or other reorganization affecting the Common Stock.  Unless otherwise provided herein or in a Participant's Option Agreement (as defined herein), Issued Shares will continue to be Issued Shares in the hands of any holder other than the Participant (except for the Company), and each such transferee thereof will succeed to the rights and obligations of a holder of Issued Shares hereunder.

" Option Agreement " shall have the meaning set forth in Section 6.1 .

" Options " shall have the meaning set forth in the preamble to this Plan.

" Option Shares " means (i) all shares of Common Stock issuable upon the exercise of an Option and (ii) all shares of any other class of Common Stock issuable upon the exercise of an Option as a result of an adjustment to such Option pursuant to any provision hereof.

" Participant " means any (a) executive or other employee of the Company or any of its Subsidiaries, (b) member of the Board (but excluding any employee or Affiliate of (i) the Company or any Subsidiary or (ii) BSMB), or (c) consultant to the Company, in each case, who has been selected to participate in the Plan by the Committee.

" Permitted Transferee " shall have the meaning set forth in Section 5.8(a) .

" Person " means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization, a governmental entity or any department, agency or political subdivision thereof or any other entity or organization.


 

" Public Company " means any Person that is required to file periodic reports with the Securities and Exchange Commission pursuant to the requirements of Sections 13 or 15 of the Securities and Exchange Act.

" Public Offering " means an underwritten public offering and sale of Common Stock pursuant to an effective registration statement under the Securities Act; provided , that a Public Offering shall not include an offering made in connection with a business acquisition or combination pursuant to a registration statement on Form S ‑4 or any form for similar registration purposes, or an employee benefit plan pursuant to a registration statement on Form S ‑8 or any form for similar registration purposes.

" Public Sale " means the sale of Issued Shares to the public pursuant to an offering registered under the Securities Act or, after the consummation of an initial Public Offering, to the public pursuant to the provisions of Rule 144 (or any similar rule or rules then in effect) under the Securities Act.

" Qualified Public Offering " means a Public Offering which results in proceeds (net of underwriting discounts and selling commissions) of an aggregate (together with proceeds from all previous Public Offerings) of at least $100,000,000 and after which the Company's equity securities are listed on a national securities exchange or the NASDAQ Stock Market; provided , that a Qualified Public Offering shall not include any issuance of equity securities in any merger or other business combination.

" Repurchase Notice " shall have the meaning set forth in Section 5.7(b) .

" Repurchase Option " shall have the meaning set forth in Section 5.7(a) .

" Repurchase Window " shall have the meaning set forth in Section 5.7(d) .

" Sale of the Company " means any transaction (other than pursuant to a Public Offering) involving the Company or UHS and an Independent Third Party or affiliated group of Independent Third Parties pursuant to which such party or parties acquire (i) a majority of the outstanding shares of capital stock of the Company or UHS (whether by merger, consolidation, sale of the capital stock or otherwise) or (ii) all or substantially all of the assets of the Company or UHS, as determined on a consolidated basis.

" Stockholders Agreement " means the Stockholders Agreement, dated as of May 31, 2007, by and among the Company and certain of the Company's stockholders, as amended or modified from time to time.

" Subsidiary " means, with respect to any Person, any corporation, partnership, limited liability company, association or other business entity of which (i) if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (ii) if a partnership, limited liability company, association or other business entity, a majority of the partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more Subsidiaries of that Person or a


 

combination thereof.  For purposes hereof, a Person or Persons shall be deemed to have a majority ownership interest in a partnership, limited liability company, association or other business entity if such Person or Persons shall be allocated a majority of partnership, limited liability company, association or other business entity gains or losses or shall be or control the managing director, managing member, manager or a general partner of such partnership, limited liability company, association or other business entity.  Where not otherwise indicated, the term " Subsidiary " refers to a Subsidiary of the Company.

" Termination Date " means, with respect to any Participant, the date that a Termination Event has occurred.

" Termination Event " means (i) with respect to any Participant that is an executive or other employee of the Company or any Subsidiary, that such Participant has ceased to be employed by the Company or any of its Subsidiaries for any reason (including as a result of such Participant's disability, death or, to the extent that such Participant entered into an employment agreement with the Company, the non ‑renewal of such employment agreement), (ii) with respect to any Participant that is a member of the Board, that such Participant had ceased to be a member of the Board for any reason or (iii) with respect to any Participant that is a consultant of the Company or any Subsidiary, that such Participant had ceased to provide consulting services to the Company or any of its Subsidiaries for any reason.

" Transfer " shall have the meaning set forth in Section 5.8(a) .

" Transfer Notice " shall have the meaning set forth in Section 5.8(a) .

" UHS " means Universal Hospital Services, Inc., a Delaware corporation and a wholly ‑owned subsidiary of the Company.

" Valuation Date " means, with respect to any Repurchase Option, the date, if any, that the Company delivers a Repurchase Notice to a holder of Issued Shares.

ARTICLE III

Administration

The Plan shall be administered by the Committee.  Subject to the limitations of the Plan, the Committee shall have the sole and complete authority to:  (i) select Participants, (ii) grant Options to Participants in such forms and amounts and with such exercise price as it shall determine, (iii) impose such limitations, restrictions and conditions upon such Options as it shall deem appropriate in accordance with the terms of the applicable Option Agreement (as defined below), (iv) interpret the Plan and adopt, amend and rescind administrative guidelines and other rules, procedures and regulations relating to the Plan, (v) correct any defect or omission or reconcile any inconsistency in the Plan or in any Options granted under the Plan in accordance with the terms of the applicable Option Agreement and (vi) make all other determinations and take all other actions necessary or advisable for the implementation and administration of the Plan.  The Committee's determinations on matters within its authority shall be conclusive and binding upon the Participants, the Company and all other Persons, except, with respect to any Options held by any Participant, as otherwise provided in the Option Agreement for such Options or in such


 

Participant's employment agreement.  All expenses associated with the administration of the Plan shall be borne by the Company.  The Committee may, as approved by the Board and to the extent permissible by law, delegate any of its authority hereunder to such Persons as it deems appropriate.

ARTICLE IV

Limitation on Aggregate Shares

The number of shares of Common Stock with respect to which Options may be granted under the Plan shall not exceed, in the aggregate, 43,904,773 shares of Common Stock, subject to adjustment in accordance with Section 6.4 and 6.5 .  To the extent any Options expire unexercised or are canceled, terminated or forfeited in any manner without the issuance of Common Stock thereunder, the shares with respect to which such Options were granted shall again be available under the Plan.  Similarly, if any shares of Common Stock issued hereunder upon exercise of the Options are repurchased hereunder, such shares shall again be available under the Plan for reissuance as Options.  The shares of Common Stock available under the Plan may be either authorized and unissued shares, treasury shares or a combination thereof, as the Committee shall determine.

ARTICLE V

Awards

5.1 Grant of Options .  The Committee may grant Options to Participants from time to time in accordance with this Article V . Options granted under the Plan shall be nonqualified stock options.  The exercise price per share of Common Stock under each Option shall be determined by the Committee at the time of grant, but shall be no less than the "fair market value" of the Common Stock on the date such Options are granted.  For purposes of this Section 5.1 only, "fair market value" of Common Stock means (a) if the stock is not readily tradable on an established securities market, the amount determined by the Board by the reasonable application of a reasonable valuation method within the meaning of Treas. Reg. §1.409A ‑1(b)(5)(iv)(B) or (b) if the stock is readily tradable on an established securities market, the fair market value of the stock based upon the last sale before or the first sale after the grant of such stock.  Subject to Section 5.6 , Options shall be exercisable at such time or times as the Committee shall determine.

5.2 Exercise Procedure .  

(a) Options shall be exercisable, to the extent they are vested, by written notice to the Company (to the attention of the Company's Secretary or any other designee set forth in the Option Agreement) accompanied by payment in full of the applicable exercise price.  Payment of such exercise price shall be made, at the election of the Participant, (i) in cash (including check, bank draft, money order or wire transfer of immediately available funds), (ii) by delivery of outstanding shares of Common Stock with a Fair Market Value on the date of exercise equal to the aggregate exercise price payable with respect to the Option's exercise, (iii) by authorizing the Company to withhold from issuance a number of Issued Shares issuable upon exercise of the Options which, when multiplied by the Fair Market Value of a share of Common Stock on the date


 

of exercise, is equal to the aggregate exercise price payable with respect to the Options so exercised or (iv) by any combination of the foregoing.    

(b) In the event a Participant elects to pay the exercise price payable with respect to an Option pursuant to Section 5.2(a)(ii) , (A) only a whole number of share(s) of Common Stock (and not fractional shares of Common Stock) may be tendered in payment, (B) such Participant must present evidence acceptable to the Company that such Participant has owned any such shares of Common Stock tendered in payment of the exercise price (and that such tendered shares of Common Stock have not been subject to any substantial risk of forfeiture) for at least six months prior to the date of exercise, and (C) such shares of Common Stock must be delivered to the Company.  Delivery for this purpose may, at the election of such Participant, be made either by (1) physical delivery of the certificate(s) for all such shares of Common Stock tendered in payment of the price, accompanied by duly executed instruments of transfer in a form acceptable to the Company, or (2) direction to such Participant's broker to transfer, by book entry, such shares of Common Stock from a brokerage account of such Participant to a brokerage account specified by the Company.  When payment of the exercise price is made by delivery of Common Stock, the difference, if any, between (x) the aggregate exercise price payable with respect to the Option being exercised and (y) the Fair Market Value of the shares of Common Stock tendered in payment (plus any applicable taxes) shall be paid in cash.  No Participant may tender shares of Common Stock having a Fair Market Value exceeding the aggregate exercise price payable with respect to the Option being exercised (plus any applicable taxes).

(c) In the event a Participant elects to pay the exercise price payable with respect to an Option pursuant to Section 5.2(a)(iii) , only a whole number of Issued Shares (and not fractional Issued Shares) may be withheld in payment.  When payment of the exercise price is made by withholding of Issued Shares, the difference, if any, between (x) the aggregate exercise price payable with respect to the Option being exercised and (y) the Fair Market Value of the Issued Shares withheld in payment shall be paid in cash.  No Participant may authorize the withholding of Issued Shares having a Fair Market Value exceeding the aggregate exercise price payable with respect to the Option being exercised (plus any applicable taxes).  Any withheld Issued Shares shall no longer be issuable under such Option.

(d) If, with respect to any Participant a Termination Event occurs, then, subject to Section  6.3 , such Participant shall have a period of 90 days after the Termination Date to exercise any Options that were vested as of the Termination Date; provided , that in the event of Participant's death or disability, such Participant (or such Participant's legal representatives) shall have a period of 180 days after the Termination Date to exercise any Options that were vested as of the Termination Date.

5.3 Withholding Tax Requirements .

(a) Amount of Withholding .  It shall be a condition of the exercise of any Option that the Participant exercising the Option make appropriate payment or other provision acceptable to the Company with respect to any withholding tax requirement arising from such exercise, in accordance with the Plan or the Option Agreement, as applicable.  The amount of withholding tax required, if any, with respect to any Option exercise (the " Withholding Amount ") shall be determined by the Company's Treasurer or other appropriate officer of the Company, and


 

the Participant shall furnish such information and make such representations as such officer requires to make such determination.

(b) Withholding Procedure .  If the Company determines that withholding tax is required with respect to any Option exercise, the Company shall notify the Participant of the Withholding Amount, and the Participant shall pay to the Company an amount equal to the Withholding Amount in cash (including check, bank draft, money order or wire transfer of immediately available funds), except to the extent otherwise provided in the Option Agreement. 1  All amounts paid to the Company pursuant to this Section 5.3 shall be deposited in accordance with applicable law by the Company as withholding tax for the Participant's account.  If the Treasurer or other appropriate officer of the Company determines that no withholding tax is required with respect to the exercise of any Option, but subsequently it is determined that the exercise resulted in taxable income as to which withholding is required (as a result of a disposition of shares or otherwise), the Participant shall promptly, upon being notified of the withholding requirement, pay to the Company, by means acceptable to the Company or as provided in an Option Agreement, the amount required to be withheld.

5.4 Notification of Inquiries and Agreements .  Each Participant and each Permitted Transferee (as defined herein) shall notify the Company in writing within ten (10) days after the date such Participant or Permitted Transferee (i) first obtains knowledge of any Internal Revenue Service inquiry, audit, assertion, determination, investigation, or question relating in any manner to the value of Options granted hereunder; (ii) includes or agrees (including, without limitation, in any settlement, closing or other similar agreement) to include in gross income with respect to any Option granted under this Plan (A) any amount in excess of the amount reported on Form 1099 or Form W ‑2 to such Participant by the Company, or (B) if no such Form was received, any amount; and/or (iii) exercises, sells, disposes of, or otherwise transfers an Option acquired pursuant to this Plan.  Upon request, a Participant or Permitted Transferee shall provide to the Company any information or document that is reasonably available to them relating to any event described in the preceding sentence which the Company (in its sole discretion) requires in order to calculate and substantiate any change in the Company's tax liability as a result of such event.

5.5 Conditions and Limitations on Exercise .  At the discretion of the Committee, exercised at the time of grant, Options may vest, in one or more installments, upon (i) the fulfillment of certain conditions, (ii) the passage of a specified period of time, and/or (iii) the achievement by the Company or any Subsidiary of certain performance goals.  In the event of a proposed Sale of the Company, the Committee may provide, in its discretion, by written notice to each applicable Participant, that any or all Options shall become immediately vested, and that any or all Options shall terminate if not exercised as of the date of such Sale of the Company or any other designated date, or that any such Options shall thereafter represent only the right to receive such consideration as the Committee shall reasonably deem equitable in good faith in the circumstances.


1. Gary Blackford will have the right in his Option Agreement to net amounts owed by him for any withholding taxes resulting from the exercise of any Options.


 

5.6 Expiration of Options .  In no event shall any part of any Option be exercisable after the stated date of expiration thereof.    

5.7 Right to Purchase Issued Shares Upon Termination of Employment .  Except to the extent otherwise provided in the Option Agreement (as determined by the Committee in its sole discretion at the time of grant), the provisions of this Section  5.7 shall apply to all Options. 2

(a) Repurchase Right .  If, with respect to any Participant, a Termination Event occurs, then such Participant's Issued Shares (whether held by such Participant or one or more transferees and including any Issued Shares acquired subsequent to the Termination Date) will, at the Company's election, be subject to repurchase, in whole or in part, by the Company pursuant to the terms and conditions set forth in this Section 5.7 (the " Repurchase Option ") at a price per Issued Share equal to the Fair Market Value per Issued Share determined as of the Valuation Date, less the amount of any cash or property distributed by the Company with respect to such Issued Share between the applicable Valuation Date and the closing of the applicable repurchase; provided , that notwithstanding the foregoing, if the Termination Event occurred due to a termination by the Company of such Participant's employment for Cause, then the applicable Issued Shares will be subject to the Repurchase Option at a price per Issued Share equal to the lesser of (x) a price per Issued Share equal to the Fair Market Value per Issued Share determined as of the Valuation Date, less the amount of any cash distributed by the Company with respect to such Issued Share between the applicable Valuation Date and the closing of the applicable repurchase and (y) the price paid to the Company for such Issued Share by such Participant.  Upon the occurrence of a Termination Event with respect to any Participant, such Participant's unvested Options as of the Termination Date shall terminate.    

(b) Repurchase Procedures .  The Repurchase Option is exercisable by the Company delivering written notice (the " Repurchase Notice ") to the holder or holders of the applicable Issued Shares at any time within 240 days after the later of (x) the applicable Termination Date or (y) the date that such Issued Shares were first issued.  The Repurchase Notice will set forth the number of Issued Shares to be acquired from such holder(s), an estimate of the aggregate consideration to be paid for such holder's Issued Shares and the time and place for the closing of the transaction.  If any Issued Shares are held by any transferees of the applicable Participant, the Company will purchase such Issued Shares elected to be purchased from such holder(s), pro rata according to the number of Issued Shares held by such holder(s) at the time of delivery of such Repurchase Notice (determined as nearly as practicable to the nearest share). 

(c) Closing of Repurchase .  The closing of the transactions contemplated by this Section 5.7 will take place on the date designated by the Company in the Repurchase Notice, which date will not be more than 45 days after the delivery of such notice.  The amount of the repurchase price to be paid for any Issued Shares to be purchased by the Company pursuant to a Repurchase Option shall be determined pursuant to Section 5.7(a) hereof and the aggregate amount of such repurchase price shall be referred to herein as the " Aggregate Repurchase Price ".  The Company will pay the applicable Aggregate Repurchase Price for any Issued Shares to be purchased by the Company pursuant to a Repurchase Option by delivery of a check payable to or


2. Gary Blackford's Option Agreement will provide that his Issued Shares are not subject to repurchase.


 

by wire transfer to an account or account(s) designated by the holder(s) of such Issued Shares in an aggregate amount equal to the applicable Aggregate Repurchase Price for such Issued Shares.    

(d) Restrictions on Repurchase .  Notwithstanding anything to the contrary contained in this Plan, all repurchases of Issued Shares by the Company pursuant to a Repurchase Option will be subject to applicable restrictions contained under applicable law (including Delaware law) and in the Company's and its Subsidiaries' debt and equity financing agreements that are in effect on the date designated by the Company for the closing of such repurchase in accordance with Section 5.7(c) .  If any such restrictions prohibit the repurchase of Issued Shares which the Company is otherwise entitled to make pursuant to this Section 5.7 or if such repurchase would cause a default under any of the Company's and/or its Subsidiaries' debt and/or equity financing agreements and, in either case, a Repurchase Notice has been timely delivered pursuant to Section 5.7(b) , the Company may, subject to provisions of this Section 5.7(d) , make such repurchases as soon as (i) it is permitted to do so under such restrictions and (ii) such repurchase would not cause such a default.  The Company will receive from each seller customary representations and warranties regarding the ownership of the Issued Shares, including, but not limited to, the representation that such seller has good and marketable title to such Issued Shares to be transferred free and clear of all liens, claims, encumbrances or other restrictions, but no seller will be required to provide any representations and warranties regarding the status of the Company.

(e) Termination of Repurchase Option .  The Repurchase Option set forth in this Section 5.7 shall terminate with respect to each Participant upon the consummation of an IPO.

5.8 Restrictions on Transfer of Issued Shares .

(a) Neither any Participant nor any Permitted Transferee may directly or indirectly, sell, pledge, assign, transfer or otherwise dispose of (a " Transfer ") any interest in any Issued Shares, except (i) pursuant to the provisions of Sections 5.7 or 5.10 hereof, (ii) in Public Sales, (iii) pursuant to applicable laws of descent and distribution, or (iv) among such Participant's Family Group; provided , that the restrictions contained in this Section 5.8 will continue to be applicable to Issued Shares after any Transfer of the type referred to in clause (iii) or (iv) above and, as a condition to any such Transfer, the transferees of such Issued Shares must agree in writing (which writing must be delivered to the Company) to be bound by the provisions of this Plan (unless such Transfer is pursuant to applicable laws of descent and distribution, in which case, such writing shall be entered into and delivered to the Company as soon as reasonably possible after such Transfer).  Any transferee of Issued Shares pursuant to a Transfer in accordance with clause (iii) or (iv) above is herein referred to as a " Permitted Transferee ."  Upon the proposed Transfer of any Issued Shares pursuant to clause (iii) or (iv) above, such Participant or such Permitted Transferee transferring such Issued Shares will deliver a written notice (a " Transfer Notice ") to the Company, which discloses in reasonable detail the identity of the Permitted Transferee(s).

(b) The provisions of this Section 5.8 shall terminate upon the consummation of a   Qualified Public Offering.

(c) Notwithstanding anything to the contrary in this Section 5.8 , any holder of Issued Shares who is a party to the Stockholders Agreement (including as a result of having


 

executed a joinder to the Stockholders Agreement in accordance with the terms of the Stockholders Agreement) shall be subject to the restrictions on Transfers with respect to the Issued Shares that are set forth in the Stockholders Agreement (rather than the restrictions on Transfers that are set forth in this Section 5.8 ).

5.9 Additional Restrictions on Transfer .  

(a) The certificates representing shares of Issued Shares will bear the following legend:

"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR AN EXEMPTION FROM REGISTRATION THEREUNDER.  THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE ALSO SUBJECT TO ADDITIONAL RESTRICTIONS ON TRANSFER, CERTAIN REPURCHASE OPTIONS AND CERTAIN OTHER AGREEMENTS SET FORTH IN THE ISSUER'S STOCK OPTION PLAN, A COPY OF WHICH MAY BE OBTAINED BY THE HOLDER HEREOF AT THE ISSUER'S PRINCIPAL PLACE OF BUSINESS WITHOUT CHARGE." 

The legend set forth above regarding the Plan shall be removed from the certificates evidencing any securities which cease to be Issued Shares.

(b) No holder of Issued Shares may Transfer any Issued Shares (except pursuant to an effective registration statement under the Securities Act or in a Public Sale) without first delivering to the Company an opinion of counsel reasonably acceptable in form and substance to the Company (which counsel will be reasonably acceptable to the Company) that registration under the Securities Act is not required in connection with such Transfer.  If such opinion of counsel, reasonably acceptable in form and substance to the Company, further states that no subsequent Transfer of such Issued Shares will require registration under the Securities Act, the Company will promptly upon such Transfer, deliver new certificates for such securities which do not bear the Securities Act legend set forth in this Section 5.9(a) .

5.10 Approved Sale of the Company .

(a) If the Board or the holders of a majority of the shares of voting Common Stock then outstanding approve a sale of all or substantially all of the assets of the Company or UHS (as determined on a consolidated basis) or a sale of all (or, for accounting, tax or other reasons, substantially all) of (x) the outstanding shares of Common Stock or (y) the shares of voting capital stock of UHS (in either case, whether by merger, recapitalization, consolidation, reorganization, combination or otherwise) to an Independent Third Party or group of Independent Third Parties (each such sale, an " Approved Sale "), then each holder of Issued Shares will vote for, consent to and raise no objections against such Approved Sale.  If the Approved Sale is structured as (i) a merger or consolidation, each holder of Issued Shares will waive any dissenters' rights, appraisal rights or similar rights in connection with such merger or consolidation or (ii) a sale of stock, each holder of Issued Shares will agree to sell all of his or her Issued Shares on the


 

terms and conditions approved by the holders of a majority of the shares of voting Common Stock then outstanding.  Each holder of Issued Shares or Options, as applicable, will take all necessary or desirable actions in connection with the consummation of the Approved Sale as reasonably requested by the Company including, without limitation, executing any applicable purchase agreement and, if necessary, exercising any Options.  Each holder of Issued Shares, upon execution of the applicable Option Agreement, irrevocably constitutes and appoints the Company the true and lawful attorney of such holder, with full power of substitution, in the name of such holder or the Company to give effect to this Section 5.10 , including the execution of any documentation necessary to transfer ownership of Issued Shares pursuant to an Approved Sale.  Each holder of Issued Shares, upon execution of the applicable Option Agreement, agrees that the powers granted to the Company in the immediately preceding sentence are coupled with an interest and are irrevocable by any holder of Issued Shares.

(b) If the Company or the holders of the Company's securities enter into any negotiation or transaction for which Rule 506 (or any similar rule then in effect) promulgated by the Securities and Exchange Commission may be available with respect to such negotiation or transaction (including a merger, consolidation or other reorganization), the holders of Issued Shares will, at the request of the Company, appoint a purchaser representative (as such term is defined in Rule 501) reasonably acceptable to the Company.  If any holder of Issued Shares appoints a purchaser representative designated by the Company, the Company will pay the fees of such purchaser representative, but if any holder of Issued Shares declines to appoint the purchaser representative reasonably designated by the Company, such holder will appoint another purchaser representative, and such holder will be responsible for the fees of the purchaser representative so appointed.

(c) Each holder of Issued Shares will bear their pro ‑rata share (based upon the amount of consideration received) of the costs of any sale of Issued Shares pursuant to an Approved Sale to the extent such costs are incurred for the benefit of all holders of Common Stock and are not otherwise paid by the Company or the acquiring party.  Costs incurred by any holder of Issued Shares on his or her own behalf will not be considered costs of the transaction hereunder.

5.11 Holdback Agreement .  No holder of Issued Shares will effect any sale or distribution of Common Stock during the seven days prior to or the 180 ‑day period beginning on the effective date of any underwritten Public Offering (except as part of such underwritten registration), unless the underwriters managing such underwritten Public Offering otherwise agree.

ARTICLE VI

General Provisions

6.1 Written Agreement .  Each Option granted hereunder shall be embodied in a written  agreement (the " Option Agreement ") which shall be signed by the Participant to whom the Option is granted and shall be subject to the terms and conditions set forth herein.  

6.2 Listing, Registration and Legal Compliance .  If at any time the Committee determines, in its discretion, that the listing, registration or qualification of the shares subject to Options upon any securities exchange or under any state or federal securities or other law or


 

regulation, or the consent or approval of any governmental regulatory body, is necessary as a condition to or in connection with the granting of Options or the purchase or issuance of shares thereunder, no Options may be granted or exercised, in whole or in part, unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Committee.  The holders of such Options will supply the Company with such certificates, representations and information as the Company shall reasonably request and shall otherwise cooperate with the Company in obtaining such listing, registration, qualification, consent or approval.  In the case of officers and other Persons subject to Section 16(b) of the Securities Exchange Act, the Committee may at any time impose any limitations upon the exercise of Options that, in the Committee's discretion, are necessary in order to comply with such Section 16(b) and the rules and regulations thereunder.  If the Company, as part of an offering of securities or otherwise, finds it necessary because of federal or state regulatory requirements to reduce the period during which any Options may be exercised, the Committee may, in its discretion and without the consent of the holder of any such Option, so reduce such period on not less than 15 days' written notice to the holders thereof.

6.3 Options Not Transferrable .  Options (including the right to receive Option Shares) may not be Transferred or assigned by the Participant to whom they were granted, other than by will or the laws of descent and distribution and, during the lifetime of such Participant, Options may be exercised only by such Participant (or, if such Participant is incapacitated, by such Participant's legal guardian or legal representative).  In the event of the death of a Participant, Options which are not vested on the date of death shall terminate, and the exercise of Options granted hereunder to such Participant which are vested as of the date of death may be made only by the executor or administrator of such Participant's estate or the Person or Persons to whom such Participant's rights under the Options pass by will or the laws of descent and distribution no later than 180 days after the date of such Participant's death.

6.4 Corporate Transaction .  Upon the occurrence of any "corporate transaction" as such term is defined in Treas. Reg. § 1.424 ‑1(a)(3) (including, but not limited to a corporate merger, consolidation, acquisition of property or stock, separation, reorganization, or liquidation) in which holders of Common Stock are entitled to receive (either directly or upon subsequent liquidation) stock with respect to their Common Stock, new stock rights may be substituted for the Options, but only to the extent that the requirements of Treas. Reg. § 1.424 ‑1 (without regard to the requirement described in § 1.424 ‑1(a)(2) that an eligible corporation be the employer of the optionee) would be met if the Option were a statutory option, and that the requirements of Section 409A of the Code are met.  Notwithstanding the foregoing, in the event of any proposed transaction which would represent a Sale of the Company, the Board may, in its discretion, terminate any or all of the Options by written notice to the then holders of the Options (whether vested or unvested), subject to the payment, upon the consummation of such Sale of the Company, by the Company to the then holders of Options of the difference, if any, between the consideration which the holders of such Options would receive in such transaction for the applicable Issued Shares if such holders exercised such Options (whether vested or unvested) immediately prior to such transaction and the exercise price of such Options.

6.5 Adjustment for Change in Common Stock .  In the event of a recapitalization, reorganization, stock split, stock dividend, combination of shares, consolidation, merger or other change in any class of Common Stock, the Board or the Committee shall, in order


 

to prevent the dilution or enlargement of rights under the Plan or outstanding Options, adjust (1) the number and type of shares or other consideration as to which options may be granted under the Plan, (2) the number and type of shares covered by outstanding Options, (3) the exercise prices specified therein and (4) other provisions of this Plan which specify a number of shares, all as such Board or Committee determines to be appropriate and equitable; provided , that such adjustments shall be made in a manner that does not subject Participants to any additional tax, penalties or interest pursuant to Section 409A of the Code.  In the event that the Company declares and pays an extraordinary dividend, the Board or Committee shall make appropriate provisions for supplemental distributions of cash, securities and/or other property to holders of any Options outstanding at the time of such extraordinary dividend in order to preserve the value represented by such Options; provided , that such supplemental distributions shall be made in a manner that does not subject Participants to any additional tax, penalties or interest pursuant to Section 409A of the Code.

6.6 Rights of Participants .  Nothing in the Plan shall interfere with or limit in any way the right of the Company or any Subsidiary to terminate any Participant's employment at any time (with or without cause), or confer upon any Participant any right to continue in the employ of the Company or any Subsidiary for any period of time or to continue to receive such Participant's current (or other) rate of compensation, the terms of which shall be governed by such Participant's employment agreement, if any, with the Company or any of its Subsidiaries.  No employee of the Company or any of its Subsidiaries shall have a right to be selected as a Participant or, having been so selected, to be selected again as a Participant, except as expressly provided in such employee's employment agreement, if any, with the Company or any of its Subsidiaries.

6.7 Amendment, Suspension and Termination of Plan .  The Board or the Committee may suspend or terminate the Plan or any portion thereof at any time and may amend it from time to time in such respects as the Board or the Committee may deem advisable; provided , however, that no such amendment shall be made without shareholder approval to the extent such approval is required by law, agreement or the rules of any exchange upon which the Common Stock is listed, and no such amendment, suspension or termination shall impair the rights of Participants under outstanding Options without the consent of the Participants affected thereby, except as provided below.  No Options shall be granted hereunder after the tenth anniversary of the adoption of the Plan.

6.8 Amendment of Outstanding Options .  The Committee may amend or modify any Option in any manner; provided , that, except as expressly contemplated elsewhere herein or in any agreement evidencing such Option, no such amendment or modification shall impair the rights of any Participant under any outstanding Option without the consent of such Participant.

6.9 Indemnification .  In addition to such other rights of indemnification as they may have as members of the Board or the Committee, the members of the Board and Committee shall be indemnified by the Company against (i) all costs and expenses reasonably incurred by them in connection with any action, suit or proceeding to which they or any of them may be party by reason of any action taken or failure to act under or in connection with the Plan or any Option granted under the Plan, and (ii) all amounts paid by them in settlement thereof (provided such settlement is approved by independent legal counsel selected by the Company) or paid by them in


 

satisfaction of a judgment in any such action, suit or proceeding; provided , however, that any such Board or Committee member shall be entitled to the indemnification rights set forth in this Section 6.9 only if such member (1) acted in good faith and in a manner that such member reasonably believed to be in, and not opposed to, the best interests of the Company, and (2) with respect to any criminal action or proceeding, (A) had no reasonable cause to believe that such conduct was unlawful, and (B) upon the institution of any such action, suit or proceeding, a Board or Committee member shall give the Company written notice thereof and an opportunity to handle and defend the same before such Board or Committee member undertakes to handle and defend it on his own behalf.

6.10 Restricted Securities .  All Common Stock issued upon the exercise of any Options issued pursuant to the terms of this Plan shall constitute "restricted securities," as that term is defined in Rule 144 promulgated by the Securities and Exchange Commission pursuant to the Securities Act, and may not be Transferred except in compliance with the registration requirements of the Securities Act or an exemption therefrom.

6.11 Amendment to Comply with Section 409A of the Code .  To the extent that this Plan or any part thereof is deemed to be a nonqualified deferred compensation plan subject to Section 409A of the Code and the Treasury Regulations (including proposed regulations) and guidance promulgated thereunder, (a) the provisions of this Plan shall be interpreted in a manner to the maximum extent possible to comply with Section 409A of the Code in accordance with Section 409A of the Code and (b) the parties hereto agree to amend this Plan for purposes of complying with Section 409A of the Code promptly upon issuance of any Treasury regulations or guidance thereunder; provided , that any such amendment shall not enlarge or diminish the number of shares of Common Stock with respect to which Options may be granted under the Plan, or otherwise materially adversely affect the Participant, the Company, or any affiliate of the Company, without the consent of such party.

6.12 Governing Law; Jurisdiction .  All issues and questions concerning the construction, validity, interpretation and enforceability of this Plan shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.  The parties hereto hereby irrevocably and unconditionally submit to the exclusive jurisdiction of any Federal court sitting in the State of Minnesota over any suit, action or proceeding arising out of or relating to this Plan.  The parties hereby agree that service of any process, summons, notice or document by U.S. registered mail addressed to any such party shall be effective service of process for any action, suit or proceeding brought against a party in any such court.  The parties hereto hereby irrevocably and unconditionally waive any objection to the laying of venue of any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.  The parties hereto agree that a final judgment in any such suit, action or proceeding brought in any such court shall be conclusive and binding upon any party and may be enforced in any other courts to whose jurisdiction any party is or may be subject, by suit upon such judgment.

*    *    *    *    *


UHS Holdco , Inc.

6625 West 78th Street, Suite 300

Minneapolis, Minnesota 55439-2604

 

 

November   [__], 2014

 

 

[Grantee]

[Grantee Address]

 

 

Re: UHS Holdco, Inc. Option Agreement – Option Enhancements

 

Dear _____________:

 

 

UHS recognizes that the success of our company is closely tied with the continued and long-term efforts of our employees. During your tenure with UHS, you ha ve been granted stock options to purchase shares of common stock of UHS Holdco, Inc. (the “Company”) because you are a key m ember of our team.   Y our grant, as evidenced by one or more Option Agreements, includes options which vest on the terms and subject to the conditions set forth in the UHS Holdco, Inc. Stock Option Plan.

 

To ensure that you  a re rewarded for your ongoing commitment to the Company , we are pleased to announce that your [xx,000] stock options have been re-priced to a lower exercise price of $0.71 per share, which will enhance your financial reward for contributing to the Company’s future growth.

 

The Company’s Board of Directors has   amended the existing Option Agreements to extend the expiration date of such options to be November 4 , 2024   and to reset the option exercise price at $0.71 per share , which was the fair market value of the Company’s common stock on the date of the amendment as determined by the Board on November  4 , 2014 . The re-pricing means that any increase in the Company’s stock price from the current value of $0.71 will increase the value of your options.   There is no limit on the gains you can realize – the higher we can drive the Company’s stock price, the more money your options are worth!

 

 

 

 

The specific changes to your Option Agreements are as follows: (a) The definition of “Exercise Price” set forth in Section 1 of each Option Agreement is amended to be an exercise price per share of $0.71; and (b) Section 4(a) of each Option Agreement is amended to strike the sentence “The Option shall not be exercisable in any event ten years after the date hereof.” appearing therein, and to replace it with the following sentence:  “The Option shall not be exercisable in any event after November 4, 2024 .”   Except as set forth in this letter, each Option Agreement shall otherwise remain in full force and effect.

 

Because the changes described in this letter are beneficial to you as an option holder, your consent to the changes is not required.  Accordingly, the purpose of this letter is simply to notify you of the actions taken and to thank you for your continued service to UHS.

 

 

Very truly yours,

 

Gary D. Blackford

Chairman

 

Recap: How Do My Stock Options Work?

A stock option is the right (but not the obligation) to purchase a share of the company’s stock at a set exercise price.

The exercise price is typically equal to the fair market value of the Company’s common stock on the date the grant is made.

Options are “gains only” equity vehicles, meaning an option is only valuable to the extent the company’s fair market price increases from the exercise price in the future. For example:

 

 

Original
Grant

Re-priced
Grant

 

 

Exercise price

$1.00

$0.71

 

 

Future fair market price

$1.25

$1.25

 

 

Gain per share

$0.25

$0.54

 

 

Total number of options granted

1,000

1,000

 

 

Total gain

$250

$540

 

UHS stock options may be exercis ed   at any time after they have vested and before they have expired by providing written notice to the Company .

 

- 1 -


 

Exhibit  31.1

 

Certification of Principal Executive Officer Pursuant to Section  302 of the Sarbanes-Oxley Act of 2002

 

I, Gary D. Blackford, certify that:

 

1. I have reviewed this quarterly report on Form  10-Q of Universal Hospital Services , I nc. (the registrant );

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant s other certifying officer (s)  and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules  13a-15 (e)  and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules  13a-15 (f)  and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the registrant s most recent fiscal quarter (the registrant s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting; and

 

5. The registrant s other certifying officer (s)  and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant s auditors and the audit committee of the registrant s board of directors (or persons performing the equivalent functions):

 

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant s ability to record, process, summarize and report financial information; and

 

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant s internal control over financial reporting.

 

 

 

Date: November 6 , 2014

/s/ Gary D. Blackford

 

Gary D. Blackford

 

Chairman of the Board and

 

Chief Executive Officer

 

(Principal Executive Officer)

 


 

 

 

 


 

Exhibit 31.2

 

Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, James B. Pekarek, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Universal Hospital Services, Inc. (the registrant );

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the registrant s most recent fiscal quarter (the registrant s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting; and

 

5. The registrant s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant s auditors and the audit committee of the registrant s board of directors (or persons performing the equivalent functions):

 

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant s ability to record, process, summarize and report financial information; and

 

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant s internal control over financial reporting.

 

 

 

Date: November 6 , 2014

/s/ James B. Pekarek

 

James B. Pekarek

 

Executive Vice President and

 

Chief Financial Officer

 

(Principal Financial Officer)

 


 

 

 

 


 

Exhibit  32.1

 

CERTIFICATION PURSUANT TO

SECTION   906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Universal Hospital Services ,   I nc. (the Company ) on Form   10-Q for the period ended September 30, 2014, as filed with the Securities and Exchange Commission (the Report ) ,   I , Gary D. Blackford, Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section   906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section  13 (a)  or 15 (d)  of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

Date: November 6 , 2014

 

 

 

/s/ Gary D. Blackford

 

Gary D. Blackford

 

Chairman of the Board and

 

Chief Executive Officer

 

 

 


 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Universal Hospital Services, Inc. (the Company ) on Form 10-Q for the period ended September 30, 2014, as filed with the Securities and Exchange Commission (the Report ), I, James B. Pekarek, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

Date: November 6 , 2014

 

 

 

/s/ James B. Pekarek

 

James B. Pekarek

 

Executive Vice President and

 

Chief Financial Officer